[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3076
1. Tracey JY, Moossa AR: Unusual tumours of the pancreas. Surgeon; 2009 Aug;7(4):216-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual tumours of the pancreas.
  • All pancreatic masses are not necessarily the dismal pancreatic ductal adenocaricoma (PDA) and do not necessarily deserve a gloomy prognosis or a nihilistic attitude.
  • We review a rarer group of pancreatic lesions and discuss their pathogenesis, diagnosis and treatment.
  • BACKGROUND: The advent of more sophisticated and ever widely employed imaging modalities has identified the presence of many unsuspected unusual masses in the pancreas.
  • These lesions display natural histories and biological behaviours distinct from adenocarcinoma of the pancreas (PDA).
  • Though the list is long they include neuroendocrine tumours, cystic tumours, primary pancreatic lymphoma, solid pseudopapillary tumours, connective tissue tumours, metastatic lesions to the pancreas and many others.
  • [MeSH-major] Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736888.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 50
  •  go-up   go-down


2. Dawelbait G, Winter C, Zhang Y, Pilarsky C, Grützmann R, Heinrich JC, Schroeder M: Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data. Bioinformatics; 2007 Jul 1;23(13):i115-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data.
  • MOTIVATION: Pancreatic ductal adenocarcinoma (PDAC) eludes early detection and is characterized by its aggressiveness and resistance to current therapies.
  • RESULTS: Here, we take such a network-centric approach to pancreas cancer by re-constructing networks from known interactions and by predicting novel protein interactions from structural templates.
  • Our analysis indicates that the alteration of the calcium pathway plays an important role in pancreas-specific tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Gene Expression Profiling / methods. Models, Biological. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646287.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


3. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C: The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol; 2007 Sep;31(3):567-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.
  • The prognosis of advanced pancreatic cancer is poor.
  • We investigated how far a combination of trichostatin A (TSA) and gemcitabine synergizes to inhibit proliferation and promotion of apoptosis of pancreatic adenocarcinoma cells in vitro.
  • The human pancreatic carcinoma cells YAPC, DANG and Panc-89 and primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with gemcitabine und TSA alone (10(-4) to 10(-8) M) or together (10(-6) to 10(-7) M).
  • Combination of TSA and gemcitabine shows promise for treatment of pancreatic cancer in vivo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma / drug therapy. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Hydroxamic Acids / administration & dosage. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671683.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


Advertisement
4. Chang CL, Wu TC, Hung CF: Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther; 2007 Aug;14(16):1189-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1035-42 [10706121.001]
  • [Cites] Gene Ther. 2007 Jan;14(1):20-9 [16915291.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7 [10779556.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] J Leukoc Biol. 2000 Dec;68(6):793-806 [11129646.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):859-63 [11221870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]
  • [Cites] Vaccine. 2001 Nov 12;20(3-4):421-9 [11672905.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):356-60 [11676395.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3677-84 [11848542.001]
  • [Cites] Gene Ther. 2002 Feb;9(3):208-13 [11859424.001]
  • [Cites] Immunology. 2002 Sep;107(1):39-45 [12225361.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:d55-68 [12456324.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] Nat Med. 2003 Jan;9(1):33-9 [12496961.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):600-7 [12566302.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3162-70 [12626574.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):20-4 [12669466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5 [12857959.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):976-83 [14601058.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] IDrugs. 2003 Dec;6(12):1155-64 [14666426.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Immunity. 1995 Aug;3(2):165-9 [7648389.001]
  • [Cites] Annu Rev Immunol. 1997;15:617-48 [9143702.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):89-94 [10728600.001]
  • (PMID = 17581599.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Vaccines, DNA; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS321551; NLM/ PMC3182456
  •  go-up   go-down


5. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer; 2007 Apr 15;109(8):1561-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
  • BACKGROUND: Erlotinib, in combination with gemcitabine, has shown clinical benefits in pancreatic adenocarcinoma patients.
  • The presence of EGFR mutations and increased EGFR copy numbers in pancreatic adenocarcinoma was explored.
  • METHODS: Sixty-six pancreatic cancer patients were included in the analysis.
  • RESULTS: In the current study the EGFR mutation was harbored in only 1 (1.5%) of the 66 inoperable or metastatic pancreatic adenocarcinoma patients.
  • There was only 1 patient, who had a highly increased EGFR copy number (> or =6.0 per cell), who died, 2.1 months from the date of diagnosis.
  • The EGFR amplification did not significantly influence survival in pancreatic adenocarcinoma patients (P = .935).
  • Thirty-two (49%) of the 65 pancreatic adenocarcinomas examined harbored a point mutation in codons 12 (n = 31) and 61 (n = 1) of the KRAS gene.
  • The presence of a point mutation in codon 12 adversely influenced survival of pancreatic cancer patients (P = .030).
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Pancreatic Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics


6. Reuss R, Aberle S, Klingel K, Sauter M, Greschniok A, Franke FE, Padberg W, Blin N: The expression of the carboxyl ester lipase gene in pancreas and pancreatic adenocarcinomas. Int J Oncol; 2006 Sep;29(3):649-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of the carboxyl ester lipase gene in pancreas and pancreatic adenocarcinomas.
  • Since pancreatic cancer is an aggressive and often incurable malignancy, we investigated if the carboxyl ester lipase gene (CEL) is specifically expressed in pancreatic tissues and its promoter can be used for a specific suicide gene approach.
  • Twenty-five tumor samples, 24 samples of normal pancreatic tissue and control tissues from other organs were examined by radioactive in situ hybridization (ISH) to localize CEL mRNA.
  • By ISH, we verified a strong CEL gene expression in acinar cells of the normal pancreas.
  • In summary, these results show that, contrary to notable expression of carboxyl ester lipase in acinar cells of normal pancreatic tissue, this lipase is not significantly active in pancreatic adenocarcinomas and thus not an apt genetic marker for diagnostic or therapeutic approaches.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Expression Regulation, Enzymologic / physiology. Lipase / genetics. Pancreas / enzymology. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / genetics. Carcinoma, Acinar Cell / enzymology. Carcinoma, Acinar Cell / genetics. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Pancreatic Ductal / genetics. Humans. In Situ Hybridization. Liver Neoplasms / enzymology. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Pancreatitis / enzymology. Pancreatitis / genetics. RNA Probes. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865281.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA Probes; 0 / RNA, Messenger; EC 3.1.1.3 / CEL protein, human; EC 3.1.1.3 / Lipase
  •  go-up   go-down


7. Leiman G: My approach to pancreatic fine needle aspiration. J Clin Pathol; 2007 Jan;60(1):43-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My approach to pancreatic fine needle aspiration.
  • Pancreatic fine needle aspiration cytopathology has earned a reputation as a rapid, safe, accurate and cost-beneficial modality of investigation of pancreatic mass lesion.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Humans. Patient Selection

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] Acta Cytol. 1983 Sep-Oct;27(5):500-4 [6578648.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Diagn Cytopathol. 1985 Apr-Jun;1(2):105-10 [3836074.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):69-71 [3720483.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):72-5 [3522134.001]
  • [Cites] Acta Cytol. 1986 Jul-Aug;30(4):430-4 [3461652.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):39-42 [3336955.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):43-8 [2447722.001]
  • [Cites] Acta Cytol. 1988 Jul-Aug;32(4):447-51 [3400383.001]
  • [Cites] Acta Cytol. 1992 Sep-Oct;36(5):655-60 [1523921.001]
  • [Cites] Acta Cytol. 1992 Nov-Dec;36(6):881-6 [1449026.001]
  • [Cites] Am J Clin Pathol. 1992 Nov;98(5):478-88 [1283055.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):889-93 [8249508.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):908-12 [8249512.001]
  • [Cites] AJR Am J Roentgenol. 1988 Sep;151(3):493-4 [3261508.001]
  • [Cites] Acta Radiol. 1988 Sep-Oct;29(5):535-9 [3048349.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):37-45 [8807250.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):396-410 [8834314.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):975-9 [8842177.001]
  • [Cites] Diagn Cytopathol. 1997 Feb;16(2):112-6 [9067100.001]
  • [Cites] Am Surg. 1997 Aug;63(8):675-9; discussion 679-80 [9247432.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1329-33 [9707060.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):423-7 [9839131.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3 [10367874.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):1111-5 [10425311.001]
  • [Cites] Diagn Cytopathol. 2005 Feb;32(2):65-9 [15637684.001]
  • [Cites] Diagn Cytopathol. 2005 Apr;32(4):204-10 [15754366.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):697-707 [16203289.001]
  • [Cites] Gut. 2000 Feb;46(2):244-9 [10644320.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2255-60 [11007226.001]
  • [Cites] Diagn Cytopathol. 1988;4(4):316-22 [3254809.001]
  • [Cites] Diagn Cytopathol. 1989;5(3):263-8 [2551616.001]
  • [Cites] Acta Cytol. 1989 Nov-Dec;33(6):936-9 [2686327.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):388-91 [2612315.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):408-11 [2612319.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):142-9 [2164767.001]
  • [Cites] Radiology. 1991 Jan;178(1):253-8 [1984314.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):26-9; discussion 29-30 [1824810.001]
  • [Cites] Am J Clin Pathol. 1994 Apr;101(4):483-7 [8160642.001]
  • [Cites] Aust N Z J Surg. 1994 Jun;64(6):444-6 [7912067.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):1-10 [7846994.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):23-7 [7847005.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1230-5 [7535275.001]
  • [Cites] Acta Cytol. 1995 May-Jun;39(3):485-8 [7762337.001]
  • [Cites] Diagn Cytopathol. 1995 Mar;12(2):113-9 [7774489.001]
  • [Cites] Diagn Cytopathol. 1990;6(5):336-40 [1705496.001]
  • [Cites] Surg Gynecol Obstet. 1991 Sep;173(3):193-7 [1925879.001]
  • [Cites] Acta Cytol. 1991 Sep-Oct;35(5):546-8 [1927196.001]
  • [Cites] Diagn Cytopathol. 1991;7(4):341-5 [1935510.001]
  • [Cites] Diagn Cytopathol. 1992;8(1):65-7 [1551367.001]
  • [Cites] Acta Cytol. 1992 Jul-Aug;36(4):471-6 [1636336.001]
  • [Cites] Surgery. 1995 Sep;118(3):472-8 [7652681.001]
  • [Cites] Diagn Cytopathol. 1995 Aug;13(2):120-3 [8542789.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):233-46 [8575283.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):182-90 [8629395.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):470-4 [11275888.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Endoscopy. 2001 Oct;33(10):824-31 [11571676.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):106-12 [12004358.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):291-6 [12145615.001]
  • [Cites] Cancer. 2002 Aug 25;96(4):232-9 [12209665.001]
  • [Cites] Acta Cytol. 2002 Sep-Oct;46(5):813-8 [12365212.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):325-34 [12451561.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):362-9 [12478684.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8 [12559193.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):44-50 [12589645.001]
  • [Cites] Surgery. 2003 May;133(5):459-63 [12773972.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):341-8 [12789912.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):657-62 [12920762.001]
  • [Cites] Am J Clin Pathol. 2003 Sep;120(3):398-404 [14502804.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):723-6 [14526668.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):733-8 [14526670.001]
  • (PMID = 16698956.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 89
  • [Other-IDs] NLM/ PMC1860594
  •  go-up   go-down


8. Okabayashi T, Nishimori I, Maeda H, Hanazaki K: Incidence of and predictive risk factors for intraductal papillary mucinous neoplasm of the pancreas with ordinary pancreatic cancer. J Clin Gastroenterol; 2010 Jan;44(1):75-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of and predictive risk factors for intraductal papillary mucinous neoplasm of the pancreas with ordinary pancreatic cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Pancreatic Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Papillary / epidemiology. Adenocarcinoma, Papillary / etiology. Adenocarcinoma, Papillary / pathology. Blood Glucose / metabolism. CA-19-9 Antigen / blood. Diabetes Mellitus / physiopathology. Humans. Incidence. Multivariate Analysis. Risk Factors

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564793.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / CA-19-9 Antigen
  •  go-up   go-down


9. Adhikari RC, Tuladhar A, Shrestha S, Sharma SK: Deep-seated thoracic and abdominal lesions: usefulness of ultrasound guided fine needle aspiration cytology, a 3 year experience. Nepal Med Coll J; 2010 Mar;12(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included liver (125 cases), lung (81 cases), abdominal and mediastinal lymph nodes (29 cases), ovary (14 cases), omentum (12 cases), pancreas (10 cases), kidney (10 cases), mediastinum (8 cases), gall bladder (8 cases) etc.
  • The aim of this study was to evaluate the overall utility of ultrasonographic guided FNAC in the diagnosis of abdominal and thoracic lesions.
  • In 264 cases (82.5%), FNAC was diagnostic with commonest diagnosis being malignant neoplasm (70.0%).
  • In liver, Metastatic adenocarcinoma is the commonest tumor, while in lung; the commonest lesion is non-small cell carcinoma.
  • [MeSH-major] Neoplasms / diagnosis. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677604.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


10. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM: Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia; 2008 Aug;10(8):782-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
  • We generated transgenic mice (BK5.COX-2) in which elevation of COX-2 and its effectors trigger a metaplasia-dysplasia sequence in exocrine pancreas.
  • By 6 to 8 months, strongly dysplastic features suggestive of pancreatic ductal adenocarcinoma emerge in the metaplastic ducts.
  • Alterations in biomarkers associated with human inflammatory and neoplastic pancreatic disease were detected using immunohistochemistry.
  • The abnormal pancreatic phenotype can be completely prevented by maintaining mice on a diet containing celecoxib, a well-characterized COX-2 inhibitor.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2007 Nov;9(11):979-86 [18030366.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Am J Clin Oncol. 2007 Oct;30(5):526-30 [17921715.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):139-46 [10657949.001]
  • [Cites] Genes Dev. 2000 Sep 1;14(17):2123-33 [10970876.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Jul;226(7):692-700 [11444106.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1403-4 [12045253.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):41-8 [15671526.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):575-84 [15681840.001]
  • [Cites] Cell Res. 2005 Jan;15(1):72-7 [15686632.001]
  • [Cites] Pancreas. 2005 Mar;30(2):148-57 [15714137.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):817-23 [15609315.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1808-13 [15753378.001]
  • [Cites] Gut. 2005 Apr;54(4):510-4 [15753536.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jun;55(6):559-64 [15726370.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1217-24 [15477758.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):436-9 [15982220.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1157-64 [15920540.001]
  • [Cites] Gut. 2005 Oct;54(10):1461-7 [15870229.001]
  • [Cites] JAMA. 2005 Dec 14;294(22):2872-8 [16352795.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1943-51 [16373709.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):583-90 [16034525.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2165-78 [16762637.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):437-45 [16820089.001]
  • [Cites] ChemMedChem. 2006 Jun;1(6):603-10 [16892400.001]
  • [Cites] JOP. 2006;7(5):465-72 [16998243.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1265-70 [16979953.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3240-7 [17172427.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1856-69 [17123526.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):2012-5 [17123529.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):50-9 [17200706.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • [Cites] Pancreatology. 2001;1(4):363-8 [12120215.001]
  • [Cites] Pancreas. 2002 Jul;25(1):26-30 [12131767.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):455-63 [12189387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12483-8 [12221288.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] Nat Rev Drug Discov. 2003 Nov;2(11):879-90 [14668809.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3127-38 [14681205.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Pancreas. 2004 Jan;28(1):58-64 [14707731.001]
  • [Cites] Pancreatology. 2003;3(6):487-96 [14673200.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1235-40 [14977820.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71 [15166955.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Pancreas. 2004 Oct;29(3):179-87 [15367883.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1121-35 [1693546.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1137-46 [2350785.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):559-68 [1372155.001]
  • [Cites] Differentiation. 1994 Nov;58(1):53-64 [7532601.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Microsc Res Tech. 1997 Jun 1-15;37(5-6):509-19 [9220428.001]
  • [Cites] Cancer J Sci Am. 1998 May-Jun;4(3):194-203 [9612602.001]
  • [Cites] Biotechniques. 1998 Jun;24(6):922-4, 926, 928 [9631181.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):317-24 [10069471.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):1223-9 [10233860.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:219-30 [10415867.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):194-202 [15644546.001]
  • [Cites] Annu Rev Physiol. 2007;69:249-69 [17059357.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Histol Histopathol. 2007 Jun;22(6):661-76 [17357096.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S113-31 [17486047.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] J Leukoc Biol. 2007 Aug;82(2):204-12 [17513693.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]
  • [Cites] Pancreas. 2007 Oct;35(3):212-7 [17895840.001]
  • (PMID = 18670639.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122815; United States / NCI NIH HHS / CA / R25 CA057730; United States / NIEHS NIH HHS / ES / T32 ES07247; United States / NCI NIH HHS / CA / R21 CA122815; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NIEHS NIH HHS / ES / ES07784; United States / NIEHS NIH HHS / ES / T32 ES007247; United States / NCI NIH HHS / CA / R25CA57730; United States / NCI NIH HHS / CA / CA105345; United States / NCI NIH HHS / CA / U01 CA105345
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pyrazoles; 0 / Sulfonamides; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2481568
  •  go-up   go-down


11. Meng LX, Ding ZJ, Chen XP, Fei LS, Chi YH, Zhao ZG, Wang XF, Hao XS: [The expression and significance of nerve growth factor and its receptors in pancreatic ductal adenocarcinoma]. Zhonghua Nei Ke Za Zhi; 2009 Jul;48(7):562-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression and significance of nerve growth factor and its receptors in pancreatic ductal adenocarcinoma].
  • OBJECTIVE: To investigate nerve growth factor (beta-NGF) and its receptors expression in human pancreatic ductal adenocarcinoma.
  • METHODS: Expression and distribution of beta-NGF, tyrosine kinase A (TrKA) and P75(NGFR) were detected in operation tissue specimens of pancreatic ductal adenocarcinoma with immunohistochemistry and real-time PCR.
  • RESULTS: beta-NGF and TrKA expression are higher in pancreatic adenocarcinoma than normal pancreas, and the differences are significant (P < 0.01).
  • CONCLUSIONS: beta-NGF and TrKA might play potential roles in carcinogenesis for pancreatic cancer, have affinity with clinicopathological characters of pancreatic cancer. beta-NGF and TrKA may have mutual effect in signal transduction leading to perineural invasion of pancreatic carcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Nerve Growth Factor / metabolism. Receptor, Nerve Growth Factor / metabolism. Receptor, trkA / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957796.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptor, Nerve Growth Factor; 9061-61-4 / Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA
  •  go-up   go-down


12. Lee SE, Jang JY, Yang SH, Kim SW: Intraductal papillary mucinous carcinoma with atypical manifestations: report of two cases. World J Gastroenterol; 2007 Mar 14;13(10):1622-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1164-7 [11020905.001]
  • [Cites] Pancreas. 2006 Mar;32(2):223-4 [16552347.001]
  • [Cites] Surg Today. 2001;31(6):538-41 [11428610.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1323-4 [14535994.001]
  • [Cites] Endoscopy. 2004 Feb;36(2):186-9 [14765321.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):393-8 [15070599.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Pancreas. 2004 Apr;28(3):282-8 [15084972.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Gastroenterology. 1986 Jan;90(1):202-5 [2998918.001]
  • [Cites] J R Coll Surg Edinb. 1990 Feb;35(1):21-4 [2342004.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1636-40 [2208015.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1010-7 [9308724.001]
  • [Cites] Pancreas. 1998 Jul;17(1):100-2 [9667528.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2009-15 [9951855.001]
  • [Cites] Pancreatology. 2005;5(4-5):470-4 [15983445.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • (PMID = 17461460.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4146910
  •  go-up   go-down


13. Raina A, Greer JB, Whitcomb DC: Serology in autoimmune pancreatitis. Minerva Gastroenterol Dietol; 2008 Dec;54(4):375-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune pancreatitis (AIP) is the pancreatic manifestation of a systemic immune-driven, inflammatory process that can involve organs such as the bile duct, salivary glands and lymph nodes, in addition to the pancreas.
  • Many of the presenting signs and symptoms of AIP, including painless jaundice, weight loss and mild epigastric pain, are characteristic of pancreatic adenocarcinoma; thus, obtaining an accurate diagnosis to avoid unnecessary surgery is imperative.
  • To date, there have been studies of AIP and antibodies to lactoferrin, carbonic anhydrase isoforms II and IV, pancreatic secretory trypsin inhibitor (PSTI or SPINK) as well as to less sensitive or specific markers of autoimmunity, such as antinuclear antibody and rheumatoid factor.
  • [MeSH-major] Autoimmune Diseases / diagnosis. Pancreatitis / diagnosis. Pancreatitis / immunology

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047979.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunoglobulin G; EC 4.2.1.1 / Carbonic Anhydrases
  • [Number-of-references] 96
  •  go-up   go-down


14. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology; 2010;10(1):66-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.
  • BACKGROUND/AIMS: Pancreatic intraepithelial neoplasia (PanIN) is the most common noninvasive precursor to invasive pancreatic adenocarcinoma.
  • METHODS: Three candidate miRNAs (miR-21, miR-155, and miR-221) previously reported as overexpressed in pancreatic cancers were assessed in 31 microdissected PanINs (14 PanIN-1, 9 PanIN-2, 8 PanIN-3) using quantitative reverse transcription PCR (qRT-PCR).
  • CONCLUSIONS: Abnormalities of miRNA expression are observed in the multistep progression of pancreatic cancer, with miR-155 aberrations demonstrable at the stage of PanIN-2, and miR-21 abnormalities at the stage of PanIN-3 lesions. and IAP.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(22):6773-84 [18794355.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] J Mol Diagn. 2008 Mar;10(2):111-22 [18258927.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] PLoS One. 2008;3(7):e2557 [18596939.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2171-6 [18642050.001]
  • [Cites] World J Surg. 2009 Apr;33(4):698-709 [19030927.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):1002-11 [19293812.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Pancreatology. 2009;9(1-2):66-72 [19077456.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3918-28 [19228262.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6 [15828554.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):959-63 [15832197.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]
  • [Cites] Mod Pathol. 2007 May;20(5):570-8 [17396143.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):224-32 [17520196.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Histopathology. 2007 Oct;51(4):539-46 [17714470.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:215-39 [17506656.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1284-8 [17660710.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • (PMID = 20332664.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50CA062924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2865485
  •  go-up   go-down


15. Ferreira AM, Vaz A, Viana M, Gil-Agostinho P, Caseiro-Alves F: Case 136: intraductal papillary mucinous tumor (main duct type) of the pancreas. Radiology; 2008 Aug;248(2):695-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case 136: intraductal papillary mucinous tumor (main duct type) of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Mucinous / ultrasonography. Adenocarcinoma, Papillary / radiography. Adenocarcinoma, Papillary / ultrasonography. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / ultrasonography. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641258.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


16. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA: Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest; 2008 Feb;26(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
  • BACKGROUND: No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line treatment with a gemcitabine-based regimen.
  • There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced pancreatic cancer.
  • METHODS: Eligible patients with metastatic pancreatic adenocarcinoma were required to have an elevated serum CA19-9 (> 2x ULN) and exposure to one or two prior chemotherapy regimens, including one gemcitabine-based.
  • CONCLUSIONS: The combination of docetaxel and irinotecan given on a 21-day cycle is associated with excess toxicity in gemcitabine-refractory patients with advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / toxicity. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181045.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


17. Recchia F, Sica G, Candeloro G, Bisegna R, Bratta M, Bonfili P, Necozione S, Tombolini V, Rea S: Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study. Pancreas; 2009 Aug;38(6):e163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
  • OBJECTIVES: The antitumor activity and toxicity of a multi-step treatment were evaluated in patients with locally advanced, inoperable, or incompletely resected pancreatic (Pa) and biliary tree (Bt) adenocarcinomas (ADKs).
  • [MeSH-major] Adenocarcinoma / therapy. Biliary Tract Neoplasms / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pancreas. 2012 Jul;41(5):825. Dosage error in published abstract; MEDLINE/PubMed abstract corrected
  • (PMID = 19531969.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; EH28UP18IF / Isotretinoin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Lee KM, Yasuda H, Hollingsworth MA, Ouellette MM: Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest; 2005 Aug;85(8):1003-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells.
  • Pancreatic adenocarcinomas display foci of duct-like structures that are positive for markers of pancreatic ductal cells.
  • To create an in vitro system to study pancreatic adenocarcinomas, we had used an hTERT cDNA to immortalize primary cells of the human pancreas.
  • In this report, we show that the immortalized cells, termed hTERT-HPNE cells, have the ability to differentiate to pancreatic ductal cells.
  • Exposing hTERT-HPNE cells to sodium butyrate and 5-aza-2'-deoxycytidine lead to the formation of pancreatic ductal cells marked by the expression of MDR-1, carbonic anhydrase II, and the cytokeratins 7, 8, and 19. hTERT-HPNE cells were found to have properties of the intermediary cells formed during acinar-to-ductal metaplasia, which included their undifferentiated phenotype, expression of Nestin, evidence of active Notch signaling, and ability to differentiate to pancreatic ductal cells.
  • These results provide further evidence for the presence in the adult pancreas of a precursor of ductal cells. hTERT-HPNE cells should provide a useful model to study acinar-to-ductal metaplasia and the role played by this process in pancreatic cancer development.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Differentiation / physiology. Pancreas / cytology. Pancreatic Neoplasms / pathology. Receptors, Cell Surface / physiology. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924149.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / NOTCH2 protein, human; 0 / Receptor, Notch2; 0 / Receptors, Cell Surface
  •  go-up   go-down


19. Böttger T, Terzic A, Müller M: [Laparoscopic pancreatic resection]. Zentralbl Chir; 2006 Aug;131(4):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic pancreatic resection].
  • Over a long time laparascopy for pancreatic diseases was performed only as staging laparoscopy in order to find hidden metastasis.
  • Laparoscopic distal resection of pancreas is much more feasible due to lack of intestinal anastomoses.
  • Anyway there is only few literature about laparoscopic left pancreatic resection found.
  • RESULTS: In all four cases laparoscopic distal pancreatic resection was performed for tumor.
  • Histologic examination showed a neuroendocrine carcinoma, a serous-microcystic adenoma, a low differentiated ductal adenocarcinoma and an intraductal papillary-mucinous tumor of borderline type.
  • CONCLUSION: Laparoscopic resection of distal pancreas shows the common benefit of minimal invasive surgery for the early postoperative period and is an attractive alternative for treatment of benign and semimalign pancreatic tumors.
  • [MeSH-major] Adenoma / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Neuroendocrine / surgery. Cystadenoma, Mucinous / surgery. Laparoscopy. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004190.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Gulluoglu MG, Karayigit E, Ozden I, Kapran Y, Dizdaroglu F: Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer? Pathology; 2008 Jan;40(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?
  • We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential diagnosis of this group of cancers.
  • The expression of antibodies was also measured in ductal adenocarcinoma of the pancreatic head (DAPH).
  • METHODS: Sixty-five patients with PAC and DAPH who underwent pancreatic Whipple resection constituted the study cohort.
  • In addition to CDX2 and MUC2 antibodies, HepPar-1 immunoexpression seems to have a potential role in differential diagnosis of PACs.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Antibodies, Monoclonal / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Common Bile Duct / metabolism. Common Bile Duct / pathology. Diagnosis, Differential. Female. Homeodomain Proteins / immunology. Homeodomain Proteins / metabolism. Humans. Male. Middle Aged. Mucin-2. Mucins / immunology. Mucins / metabolism. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Retrospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038313.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


21. Egawa N, Tu Y, Sanaka M, Kamisawa T: Family history of diabetes and pancreatic cancer. Pancreas; 2005 Jan;30(1):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of diabetes and pancreatic cancer.
  • OBJECTIVES: The aim of this study was to clarify the relationship between a family history of diabetes and pancreatic cancer.
  • METHODS: We reviewed the records of 331 patients with pancreatic ductal cancer and information about a family history of diabetes in first-degree relatives.
  • Each group was further divided into 2 subgroups according to the presence of long-standing diabetes for at least 3 years before the diagnosis of the pancreatic cancer, and the 2 subgroups were also compared.
  • RESULTS: As compared with group non-FH, group FH was 4 years younger at the diagnosis of pancreatic cancer (61.33 +/- 9.00 vs. 65.46 +/- 10.48 years; P = 0.015) and showed a significant predilection for cancer of the pancreas body and/or tail (65.1% vs. 43.4%; P = 0.009).
  • CONCLUSIONS: These findings suggest that pancreatic cancer patients with a family history of diabetes have different clinical characteristics compared with those without.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / epidemiology. Carcinoma, Pancreatic Ductal / genetics. Diabetes Mellitus, Type 2 / epidemiology. Diabetes Mellitus, Type 2 / genetics. Pancreatic Neoplasms / epidemiology. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Age Distribution. Aged. Family Health. Female. Humans. Male. Middle Aged. Regression Analysis. Risk Factors


22. Mazur PK, Einwächter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G, Schmid RM, Siveke JT: Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A; 2010 Jul 27;107(30):13438-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma.
  • Pancreatic cancer is one of the most fatal malignancies lacking effective therapies.
  • Notch signaling is a key regulator of cell fate specification and pancreatic cancer development; however, the role of individual Notch receptors and downstream signaling is largely unknown.
  • Here, we show that Notch2 is predominantly expressed in ductal cells and pancreatic intraepithelial neoplasia (PanIN) lesions.
  • Using genetically engineered mice, we demonstrate the effect of conditional Notch receptor ablation in KrasG12D-driven pancreatic carcinogenesis.
  • Deficiency of Notch2 but not Notch1 stops PanIN progression, prolongs survival, and leads to a phenotypical switch toward anaplastic pancreatic cancer with epithelial-mesenchymal transition.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Receptor, Notch2 / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Disease Progression. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mice. Mice, Knockout. Pancreas / metabolism. Pancreas / pathology. Proto-Oncogene Proteins c-myc / genetics. Proto-Oncogene Proteins c-myc / metabolism. Proto-Oncogene Proteins p21(ras) / genetics. Proto-Oncogene Proteins p21(ras) / metabolism. Receptor, Notch1 / genetics. Receptor, Notch1 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction


23. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M: Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther; 2006 Dec;5(12):3240-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of celecoxib pharmacodynamics in pancreatic cancer.
  • This study aimed to determine the biological effect of the COX-2 inhibitor celecoxib in pancreatic cancer as an early step to the further development of the agent in this disease.
  • Eight patients scheduled for resection of an infiltrating adenocarcinoma of the pancreas were randomized to receive celecoxib at a dose of 400 mg twice daily or placebo for 5 to 15 days before the surgery.
  • In summary, celecoxib efficiently inhibited the synthesis of prostaglandin E2 both in pancreatic cancer surgical specimens and in xenografted carcinomas but did not exert evident antitumor, antiproliferative, or antiangiogenic effect as a single agent.
  • The direct pancreatic cancer xenograft model proved to be a valuable tool for drug evaluation and biological studies and showed similar results to those observed in resected pancreatic cancer specimens.
  • [MeSH-major] Cyclooxygenase Inhibitors / pharmacology. Pancreatic Neoplasms / drug therapy. Pyrazoles / pharmacology. Sulfonamides / pharmacology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172427.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / RNA, Messenger; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


24. Ramanarayanan J, Scarpace SL: Acute drug induced hepatitis due to erlotinib. JOP; 2007;8(1):39-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We report a case of acute severe hepatitis resulting from erlotinib monotherapy in a patient with locally advanced pancreatic cancer.
  • As EGFR inhibitors are now incorporated with chemotherapy in advanced pancreatic cancers, clinicians should be aware of this potential complication.
  • [MeSH-major] Adenocarcinoma / drug therapy. Drug-Induced Liver Injury / etiology. Pancreatic Neoplasms / drug therapy. Protein Kinase Inhibitors / adverse effects. Quinazolines / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228132.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


25. Herrmann KA, Helmberger T, Bruns C, Reiser MF, Zech CJ: [Solid pseudopapillary pancreas tumors--often neglected]. Radiologe; 2008 Aug;48(8):764-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solid pseudopapillary pancreas tumors--often neglected].
  • [Transliterated title] Solide pseudopapilläre Tumoren des Pankreas : Häufig vergessen.
  • Solid pseudopapillary tumors of the pancreas (SPTP) are rare tumors of the pancreas with low malignancy potential and a very good prognostic outcome after surgery.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2006 Dec;41(12):1992-5 [17161189.001]
  • [Cites] Surgery. 2008 Jan;143(1):29-34 [18154930.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 May;5(2):300-4 [16698596.001]
  • [Cites] Radiology. 1992 Aug;184(2):567-70 [1620866.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):200-3 [18067066.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1403-9 [15761986.001]
  • [Cites] AJR Am J Roentgenol. 2003 Aug;181(2):395-401 [12876017.001]
  • [Cites] Pathologe. 2005 Feb;26(1):41-5 [15580505.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):82-92 [8416730.001]
  • [Cites] ANZ J Surg. 2005 Aug;75(8):684-9 [16076333.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] Br J Surg. 1990 Sep;77(9):1000-3 [2207560.001]
  • [Cites] Surgery. 1995 Nov;118(5):821-8 [7482268.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):304-10 [17326131.001]
  • [Cites] Gastroenterol Clin Biol. 1999 Feb;23(2):207-14 [10353015.001]
  • [Cites] Clin Nucl Med. 2005 Mar;30(3):187-8 [15722825.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(2):179-83 [1705067.001]
  • [Cites] J Ultrasound Med. 2001 Nov;20(11):1229-32 [11758028.001]
  • [Cites] Radiographics. 1997 Mar-Apr;17 (2):453-72; quiz 472A-472B [9084084.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):289-96 [11320522.001]
  • (PMID = 18648761.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 22
  •  go-up   go-down


26. Ikeda S, Maeshiro K, Ryu S, Ogata K, Yasunami Y, Nakayama Y, Hamada Y: Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients. Pancreas; 2009 May;38(4):e102-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients.
  • OBJECTIVES: The diagnosis of small pancreatic cancer remains difficult.
  • The present study describes the diagnostic value of endoscopic balloon-catheter spot pancreatography for small pancreatic cancer.
  • METHODS: Since April 1984, balloon spot pancreatography has been used to detect small-sized pancreatic cancer in patients having possible symptoms or findings of obstructive pancreatitis.
  • RESULTS: A resection was performed on 175 of 416 patients with conditions diagnosed as pancreatic cancer.
  • Of the 175 patients, 23 (13%) had invasive carcinoma 2 cm or smaller based on histological measurements, 3 intraductal papillotubular adenocarcinoma, and 3 carcinoma in situ (CIS).
  • A definite diagnosis was obtained based on the findings of main duct stenosis or obstruction with marked stricture of the branch ducts (n = 18) and a filling defect in the main duct (n = 2).
  • CONCLUSIONS: Balloon spot pancreatography is an essential tool for the diagnosis of small ductal pancreatic cancer, and it also makes it possible to locate CIS lesions of the branch ducts.
  • [MeSH-major] Catheterization. Cholangiopancreatography, Endoscopic Retrograde / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / diagnosis. Female. Humans. Male. Middle Aged. Pancreatitis / diagnosis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287333.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Iashina NI, Karmazanovskiĭ GG, Kozlov IA, Egorov VI, Vinokurova LV: [Computer--tomographic resecability criteria at cancer head of the pancreas]. Eksp Klin Gastroenterol; 2010;(8):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Computer--tomographic resecability criteria at cancer head of the pancreas].
  • The aim of the study was to explore the possibilities of CT in evaluating resectability of pancreatic head adenocarcinoma, depending on the tumor.
  • MATERIALS: The results of CT and intraoperative findings in 62 patients with cancer of the head of the pancreas.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / surgery. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Pancreas. Pancreatectomy. Prognosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21268766.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


28. Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn JD, Kim J: The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas; 2008 Jul;37(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer.
  • OBJECTIVES: The role of lymph node (LN) dissection for pancreatic cancer remains uncertain, and guidelines for a minimum LN number have not been established.
  • We hypothesized that LN number in node-negative (N0) pancreatic cancer influences survival.
  • METHODS: The Surveillance, Epidemiology, and End Results database was queried for patients undergoing resection for N0 pancreatic adenocarcinoma between 1988 and 2003.
  • CONCLUSIONS: Pancreatic cancer lymphadenectomy with examination of >10 LN is associated with improved survival in N0 disease and should be considered a benchmark for adequacy of surgery and/or pathology.
  • [MeSH-major] Adenocarcinoma / mortality. Lymph Node Excision. Pancreatectomy. Pancreatic Neoplasms / mortality. Pancreaticoduodenectomy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580439.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


29. Tamiolakis D, Simopoulos C, Venizelos J, Lambropoulou M, Nikolaidou S, Tsikouras P, Koutsougeras G, Alexiadis G, Menegaki M, Papadopoulos N: Distribution of somatostatin in pancreatic ductal adenocarcinoma remodels the normal pattern of the protein during foetal pancreatic development: an immunohistochemical analysis. Clin Exp Med; 2005 Oct;5(3):106-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of somatostatin in pancreatic ductal adenocarcinoma remodels the normal pattern of the protein during foetal pancreatic development: an immunohistochemical analysis.
  • AIM: To determine the immunoreactivity of somatostatin during the development of the human fetal pancreas and pancreatic ductal adenocarcinoma, given that, somatostatin-positive cells were demonstrated either into its embryonic anlage or into pancreatic cancer.
  • METHODS: Tissue sections from 15 pancreatic fetal specimens, and an equal number of ductal adenocarcinoma specimens were assessed.
  • RESULTS: The density of positive cells in the primitive exocrine ductal epithelium and endocrine epithelium was significantly different from the relevant density in the neoplastic pancreatic tissue of mixed (ductal-endocrine) and pure ductal type (P1=0.021 P2=0.001, P3<0.0001, P4=0.003 respectively).
  • CONCLUSION: The immunostaining for somatostatin identifies a subgroup of pancreatic ductal adenocarcinomas with a neuroendocrine component, (initially considered as pure ductal tumors), and mixed ductal and neuroendocrine tumors.
  • This pattern of expression in neoplasms recapitulates the normal pattern during the embryonal development of the organ, raising the question of therapeutic efficacy of somatostatin and analogues as monotherapy in pancreatic cancer management.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Pancreas / embryology. Pancreatic Neoplasms / metabolism. Somatostatin / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284732.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


30. Morris JP 4th, Cano DA, Sekine S, Wang SC, Hebrok M: Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest; 2010 Feb;120(2):508-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice.
  • WT mouse acinar cells rapidly regenerate following injury that mimics acute pancreatitis, a process characterized by transient reactivation of pathways involved in embryonic pancreatic development.
  • In contrast, such injury promotes the development of pancreatic ductal adenocarcinoma (PDA) precursor lesions in mice expressing a constitutively active form of the GTPase, Kras, in the exocrine pancreas.
  • Here, we used genetically engineered mice to demonstrate that mutant Kras promotes acinar-to-ductal metaplasia (ADM) and pancreatic cancer precursor lesion formation by blocking acinar regeneration following acute pancreatitis.


31. Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK: Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol; 2006 Dec;13(12):1645-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.
  • BACKGROUND: Real-time quantitative polymerase chain reaction (qPCR) may prove to be a sensitive technique by which to evaluate potential tumor markers in pancreatic cancer.
  • METHODS: The prostate stem cell antigen (PSCA) gene was identified as a marker highly expressed in pancreatic adenocarcinoma and not normal pancreas.
  • RNA from pancreatic and nonpancreatic cancer cell lines as well as tissue and blood from pancreatic cancer and control patients was reverse-transcribed and PSCA quantified by qPCR.
  • Five of six pancreatic cell lines had PSCA/actin ratios 10-fold greater than nonpancreatic cancer lines.
  • Mean PSCA expression in pancreatic tumor tissue was significantly higher (P < 0.05, Student's t-test) than in the tissue of benign pancreatic processes.
  • PSCA copy number was significantly higher in the blood of patients with metastatic pancreatic cancer than in that of normal patients (P < 0.05, Student's t-test).
  • CONCLUSIONS: Such trends suggest that PSCA may prove to be a valuable pancreatic cancer tumor marker.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Membrane Glycoproteins / genetics. Neoplasm Proteins / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Antigens, Neoplasm. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Cell Line, Tumor. GPI-Linked Proteins. Gene Dosage. Humans. Pancreas / metabolism. Pancreas / pathology. Pancreatic Cyst / genetics. Pancreatic Cyst / metabolism. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957968.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / F32 CA 94639; United States / NCI NIH HHS / CA / K08 CA74241
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / RNA, Messenger
  •  go-up   go-down


32. Kaifi JT, Cataldegirmen G, Wachowiak R, Schurr PG, Kleinhans H, Kosti G, Yekebas EF, Mann O, Kutup A, Kalinin V, Strate T, Izbicki JR: Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis. Anticancer Res; 2007 Jan-Feb;27(1A):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.
  • Kazal-type genes are associated with cancer and pancreatic disease.
  • The aim of the present study was to examine whether ECRG2 STR polymorphisms are associated with pancreatic carcinoma and chronic pancreatitis.
  • MATERIALS AND METHODS: A total of 209 surgically treated patients were analyzed, 92 with pancreatic adenocarcinoma and 117 with chronic pancreatitis.
  • RESULTS: ECRG2 STR of highest incidence was TCA3/TCA3 [47 (51%) in pancreatic carcinoma; 59 (50%) in pancreatitis patients], followed by the TCA3/TCA4 [37 (40%); 54 (46%)] and TCA4/TCA4 [8 (9%); 4 (4%)] genotypes.
  • No correlation in frequency of STRs comparing chronic pancreatitis and pancreatic cancer was determined using the Chi-squared test (p = 0.23).
  • CONCLUSION: The data show that ECRG2 STR polymorphism TCA3/TCA3 in exon 4 is the most prevalent polymorphism found in pancreatic adenocarcinoma and chronic pancreatitis detected in peripheral blood.
  • None of the polymorphisms was associated with poor clinical outcome in pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352218.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


33. Okamoto N, Inaba K, Konno H: [Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report].
  • The prognosis for advanced pancreatic cancer with peritoneal dissemination is extremely poor, and no effective standard therapy has been established.
  • We present a case of a very old patient whose QOL improved shortly after administration of only S-1 to treat advanced pancreatic cancer with peritoneal dissemination.
  • CT scanning showed severe ascites and a low-density area 2 cm wide at the tail of the pancreas.
  • Ascitic cytology revealed adenocarcinoma and carcinomatous peritonitis due to pancreatic cancer.
  • Six months later CT scanning showed that the ascites had disappeared and that the low-density area at the tail of the pancreas had become less obvious.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620815.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


34. Brown KM, Domin C, Aranha GV, Yong S, Shoup M: Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg; 2005 Mar;189(3):278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas.
  • However, the relationship between platelet count and prognosis in pancreatic cancer remains unresolved.
  • METHODS: A chart review of patients undergoing resection for pancreatic adenocarcinoma was undertaken.
  • RESULTS: Between June 1995 and March 2003, 109 patients (63% male) with a median age of 68 years (range 42 to 85 years) underwent resection for pancreatic cancer.
  • CONCLUSIONS: Increased preoperative platelet count is associated with adverse survival outcome in patients undergoing resection for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / mortality. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / mortality. Platelet Count

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792750.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Lévy P, Hammel P, Ruszniewski P: [Autoimmune pancreatitis]. Presse Med; 2007 Dec;36(12 Pt 3):1925-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One such disease involves a bile disorder very similar to primary sclerosing cholangitis but responsive to corticosteroid treatment.
  • Chronic autoimmune pancreatitis must be routinely considered in patients with a pancreatic tumor that is for a clinical, epidemiologic, serologic or imaging reason not completely consistent with pancreatic adenocarcinoma.
  • A short corticosteroid therapy (< 4 weeks) is probably less harmful in a patient with pancreatic adenocarcinoma than pancreatectomy (or chemotherapy) in patients with chronic autoimmune pancreatitis.
  • Diagnosis depends on a body of clinical and radiologic evidence.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / therapeutic use. Antibodies, Antinuclear / analysis. Cholangiography. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Cholangitis / complications. Cholangitis / diagnosis. Chronic Disease. Colitis, Ulcerative / diagnosis. Crohn Disease / diagnosis. Endosonography. Humans. Magnetic Resonance Imaging. Pancreas / pathology. Pancreatectomy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490850.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Antinuclear
  • [Number-of-references] 64
  •  go-up   go-down


36. Desai S, Ben-Josef E, Griffith KA, Simeone D, Greenson JK, Francis IR, Hampton J, Colletti L, Chang AE, Lawrence TS, Zalupski MM: Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1450-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
  • PURPOSE: To report outcomes for patients with resected pancreas cancer treated with an adjuvant regimen consisting of gemcitabine-based combination chemotherapy followed by capecitabine and radiation.
  • Between January 2002 and August 2006, 43 resected pancreas cancer patients were offered treatment consisting of 4, 21-day cycles of gemcitabine 1 g/m(2) intravenously over 30 min on Days 1 and 8, with either cisplatin 35 mg/m(2) intravenously on Days 1 and 8 or capecitabine 1500 mg/m(2) orally in divided doses on Days 1-14.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409732.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Sceusi EL, Wray CJ: Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence. World J Surg Oncol; 2009;7:98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence.
  • BACKGROUND: Situs inversus (SI) is a relatively rare occurrence in patients with pancreatic adenocarcinoma.
  • Pancreatic resection in these patients has rarely been described.
  • CT scan imaging is a principle modality for detecting pancreatic cancer and its use in SI patients is seldom reported.
  • CASE PRESENTATION: We report a 48 year old woman with SI who, despite normal CT scan 8 months earlier, presented with obstructive jaundice and a pancreatic head mass requiring a pancreaticoduodenectomy.
  • The surgical pathology report demonstrated pancreatic adenocarcinoma.
  • CONCLUSION: SI is a rare condition with concurrent pancreatic cancer being even rarer.
  • Additionally, radiographic imaging has significantly improved detection of early pancreatic cancer; however, there continues to be a need for improved detection of small neoplasms.
  • [MeSH-major] Adenocarcinoma / complications. Pancreatic Neoplasms / complications. Situs Inversus / complications

  • Genetic Alliance. consumer health - Situs inversus.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2009 Oct;19(10):2448-55 [19415290.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8 [18948228.001]
  • [Cites] Transplant Proc. 2008 Jun;40(5):1792-5 [18589199.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):524-7 [17081721.001]
  • [Cites] Wiad Lek. 2006;59(9-10):707-9 [17338134.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):512-9 [16891882.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Semin Cell Dev Biol. 1998 Feb;9(1):89-99 [9572118.001]
  • [Cites] J Clin Gastroenterol. 1997 Mar;24(2):92-6 [9077725.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):897-903 [15039161.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):606-7 [12781900.001]
  • [Cites] Radiol Clin North Am. 2002 Dec;40(6):1263-72 [12479710.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Am J Med Genet. 2001 Jul 15;101(4):345-55 [11471158.001]
  • [Cites] Surg Radiol Anat. 2000;22(5-6):293-7 [11236325.001]
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1439-56 [12432114.001]
  • (PMID = 20021643.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803176
  •  go-up   go-down


38. Oettle H, Neuhaus P: Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs; 2007;67(16):2293-310
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy in pancreatic cancer: a critical appraisal.
  • Adenocarcinoma of the pancreas carries a grim prognosis.
  • More recently, the ESPAC (European Study Group for Pancreatic Cancer)-1 trial even indicated a detrimental effect of chemoradiotherapy, while chemotherapy with 5-FU was shown to have a significant positive impact on long-term survival.
  • More recently, gemcitabine, which is the most effective single agent in advanced pancreatic cancer, has also been evaluated in the adjuvant setting.
  • [MeSH-major] Adenocarcinoma. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / therapeutic use. Pancreatic Neoplasms

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Drugs. 2007;67(17):2487-90; discussion 2491-3 [18034586.001]
  • [CommentIn] Drugs. 2007;67(17):2481-5; discussion 2491-3 [18034585.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):235-44 [16183477.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1528-35 [9427017.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9 [8390422.001]
  • [Cites] Tumori. 1995 Jan-Feb;81(1):23-31 [7754537.001]
  • [Cites] Anticancer Drugs. 2000 Nov;11(10):771-86 [11142685.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):689-97 [16713541.001]
  • [Cites] Cancer. 1973 Dec;32(6):1341-5 [4127980.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(2):151-6 [9745081.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1483-7 [11121652.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Oncology. 2005;68(2-3):239-45 [16015040.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1185-91 [12181240.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Surg Gynecol Obstet. 1983 Sep;157(3):205-19 [6351303.001]
  • [Cites] Am J Clin Oncol. 2003 Dec;26(6):543-9 [14663369.001]
  • [Cites] Ann Oncol. 2001 May;12(5):681-4 [11432628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1081-7 [11072166.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5 [15218576.001]
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):644-50 [9684110.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Oct;13(4):663-74, ix [15350940.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):332-3; author reply 333 [16858208.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] Arch Surg. 2001 Mar;136(3):343-7 [11231859.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):806-13 [12454519.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Oct;58(4):504-8 [16633830.001]
  • [Cites] Int J Pancreatol. 1997 Feb;21(1):53-8 [9127174.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5 [15215490.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • (PMID = 17983252.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Number-of-references] 53
  •  go-up   go-down


39. Giovannini M: The place of endoscopic ultrasound in bilio-pancreatic pathology. Gastroenterol Clin Biol; 2010 Sep;34(8-9):436-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The place of endoscopic ultrasound in bilio-pancreatic pathology.
  • The place of endoscopic ultrasound (EUS) in malignant pathology of the pancreas is two-fold:.
  • (1) EUS is the best examination for the diagnosis of small tumours (<3cm in diameter).
  • The performance of EUS seems to be greater than other imaging techniques for the diagnosis of vascular and lymph node invasion although recent studies report less good results than those of studies in 1992 to 1994, particularly for vascular involvement.
  • Nevertheless, EUS cannot affirm the malignant or benign character of these pancreatic masses.
  • EUS-guided biopsy is today the best technique for obtaining the histology of a pancreatic mass, with a sensitivity of 85 to 87%.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Contrast Media. Elasticity Imaging Techniques. Endosonography / methods. Endosonography / trends. Pancreatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20579826.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


40. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E: Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma; 2009;56(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.
  • The aim of our study was to assess the clinical significance of -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms as well as TNF-alpha and INF-gamma serum levels in pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP) as regards to healthy volunteers.
  • We studied 41 patients with pancreatic adenocarcinoma, 56 with chronic pancreatitis and 50 healthy volunteers.
  • -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms probably do not play important role in pancreatic diseases.
  • Key words: pancreatic adenocarcinoma, tumor necrosis factor alpha, interferon gamma, cytokines, polymorphism.
  • [MeSH-major] Adenocarcinoma / genetics. Interferon-gamma / genetics. Pancreatic Neoplasms / genetics. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152246.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


41. Mané JM, Sancho A, Muñoz A, Rubio I, Fernández R, Carrera S, Fuente N, Ballesteros D, Casas R, Marrodán I, Mielgo X, López-Vivanco G: Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma. Tumori; 2010 May-Jun;96(3):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
  • AIMS AND BACKGROUND: Gemcitabine is an effective agent in pancreatic adenocarcinoma.
  • We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with pancreatic or biliary tree adenocarcinoma.
  • METHODS: Eligible patients with locally advanced or metastatic pancreatic or biliary tree adenocarcinoma received fixed-dose-rate gemcitabine at a dose of 1500 mg/m(2) at a rate of 10 mg/m(2)/min weekly for 3 weeks every 28 days.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845800.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


42. Demir IE, Ceyhan GO, Rauch U, Altintas B, Klotz M, Müller MW, Büchler MW, Friess H, Schäfer KH: The microenvironment in chronic pancreatitis and pancreatic cancer induces neuronal plasticity. Neurogastroenterol Motil; 2010 Apr;22(4):480-90, e112-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The microenvironment in chronic pancreatitis and pancreatic cancer induces neuronal plasticity.
  • BACKGROUND: Pancreatic neuropathy in chronic pancreatitis (CP) and pancreatic cancer (PCa) is characterized by pancreatic neuropathy, i.e. increased neural density and hypertrophy, which are associated with neuropathic pain.
  • METHODS: Dissociated myenteric plexus (MP) and dorsal root ganglia (DRG) neurons of newborn rats were treated with normal human pancreas (NP), CP or PCa tissue extracts.
  • Furthermore, MP and DRG neurons were cultured in supernatants from different pancreatic cancer cell lines (PCC) and human pancreatic stellate cells (hPSC) obtained from either CP or PCa tissues.
  • Pancreatic cancer cell supernatants induced a prominent neurite outgrowth, increased neurite density and perikaryonal hypertrophy in MP and DRG neurons.
  • Thus, due to its neurotrophic attributes, the intrapancreatic microenviroment in CP and PCa seems to be a key player in the generation of pancreatic neuropathy and neuroplasticity.
  • [MeSH-major] Adenocarcinoma / metabolism. Neuronal Plasticity / physiology. Neurons / metabolism. Pancreas / metabolism. Pancreatic Neoplasms / metabolism. Pancreatitis, Chronic / metabolism


43. Fruscalzo A, Damante G, Calcagno A, Di Loreto C, Marchesoni D: Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report. Cancer Invest; 2006 Oct;24(6):611-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several other carcinomas seem to be associated with BRCA2 mutations: pancreas, prostate, larynx, gallbladder, bile duct cancer, and malignant melanoma.
  • We described a case of a 67-year-old BRCA2 mutation carrier of Caucasian, non-Jewish, ethnic origin who successively developed 4 primary malignancies in 30 months: breast ductal carcinoma, chronic lymphatic leukemia, ovarian serous papillary carcinoma, and endocervical adenocarcinoma.
  • Chronic lymphatic leukemia and endocervical adenocarcinoma have not been yet associated to BRCA2 germline mutation.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Cystadenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / therapy. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree


44. Gardner TB, Barth RJ, Zaki BI, Boulay BR, McGowan MM, Sutton JE, Ripple GH, Colacchio TA, Smith KD, Byock IR, Call M, Suriawinata AA, Tsapakos MJ, Mills JB, Srivastava A, Stannard M, Lisovsky M, Gordon SR, Pipas JM: Effect of initiating a multidisciplinary care clinic on access and time to treatment in patients with pancreatic adenocarcinoma. J Oncol Pract; 2010 Nov;6(6):288-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of initiating a multidisciplinary care clinic on access and time to treatment in patients with pancreatic adenocarcinoma.
  • PURPOSE: Neoadjuvant therapy for pancreatic adenocarcinoma requires referral to multiple specialists before initiating therapy.
  • We evaluated the effect of establishing a multidisciplinary clinic (MDC) for patients with newly diagnosed pancreatic adenocarcinoma on treatment access and time to therapy.
  • METHODS: Patients with newly diagnosed pancreatic adenocarcinoma diagnosed and treated at our center were included.
  • The primary outcomes were days from diagnosis to first treatment (initiation of chemotherapy or external beam radiation), days to completion of all required consultations, and number of visits needed before initiation of therapy.
  • CONCLUSION: In patients with pancreatic adenocarcinoma undergoing neoadjuvant therapy, the establishment of a multidisciplinary pancreas tumor clinic led to improved patient access to consultations and shorter time to initial treatment.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):995-1004 [16252135.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2117-27 [14645640.001]
  • [Cites] J Am Coll Surg. 2008 Mar;206(3):451-7 [18308215.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Jun;54(2):161-76 [18319689.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2081-8 [18461404.001]
  • [Cites] Int J Qual Health Care. 2009 Apr;21(2):137-44 [19147593.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1231-7 [11283921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22 [11483344.001]
  • [Cites] JAMA. 2002 Oct 16;288(15):1909-14 [12377092.001]
  • [Cites] Mod Pathol. 2003 May;16(5):515-8 [12748259.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2720-6 [15187053.001]
  • [Cites] Int J Qual Health Care. 2005 Apr;17(2):141-6 [15665066.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] JAMA. 2010 Mar 17;303(11):1054-61 [20233823.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):317-23 [9440759.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Health Policy. 2003 Sep;65(3):227-41 [12941491.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2346-51 [16998942.001]
  • (PMID = 21358957.001).
  • [ISSN] 1935-469X
  • [Journal-full-title] Journal of oncology practice
  • [ISO-abbreviation] J Oncol Pract
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2988661
  •  go-up   go-down


45. Freitas D, Fernandes Gdos S, Hoff PM, Cunha JE: Medical management of pancreatic adenocarcinoma. Pancreatology; 2009;9(3):223-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of pancreatic adenocarcinoma.
  • Pancreatic cancer is the fourth leading cause of cancer death in the United States.
  • In 2008, an estimated 34,290 people died from pancreatic cancer and 37,680 new cases were diagnosed.
  • Despite modern treatment, 90% of patients die within 1 year of diagnosis.
  • In the present paper the English-language literature addressing the medical management in pancreatic cancer was reviewed.
  • Based on these data we will discuss the role of currently used chemotherapy and target therapy in pancreatic cancer, as well as perspectives of the emerging strategies that are arising in order to improve the outcomes of this complex disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19420981.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


46. Donadelli M, Dalla Pozza E, Costanzo C, Scupoli MT, Scarpa A, Palmieri M: Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. J Cell Biochem; 2008 May 1;104(1):202-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
  • We investigated the ability of the zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) to reduce pancreatic cancer cell viability.
  • TPEN was much more efficient to inhibit pancreatic adenocarcinoma cell growth than a panel of anti-cancer drugs, including 5-fluorouracil, irinotecan, cisplatin, edelfosine, trichostatin A, mitomycin C, and gemcitabine, the gold standard chemotherapeutic agent for pancreatic cancer.
  • Moreover, TPEN showed a dose- and time-dependent anti-proliferative effect significantly higher on pancreatic cancer cells than on normal primary fibroblasts.
  • This effect may be explained by a significantly higher zinc depletion by TPEN in pancreatic cancer cells as compared to fibroblasts.
  • In this study, we suggest that zinc depletion may be an efficient strategy in the treatment of pancreatic cancer because of its reduced antiproliferative effect on normal cells.
  • [MeSH-major] Cell Proliferation / drug effects. Ethylenediamines / pharmacology. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / therapy. Zinc / deficiency

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979179.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Ethylenediamines; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; J41CSQ7QDS / Zinc
  •  go-up   go-down


47. Takahashi S, Homma H, Akiyama T, Mesawa S, Hirata K, Kogawa K, Takanashi K, Ishiwatari H, Kawano Y, Hayashi T, Takada K, Miyanishi K, Kato J, Niitsu Y: [A case of intraductal papillary mucinous neoplasm with internal pancreatic fistula causing left ureteral obstruction]. Nihon Shokakibyo Gakkai Zasshi; 2007 Aug;104(8):1236-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of intraductal papillary mucinous neoplasm with internal pancreatic fistula causing left ureteral obstruction].
  • A 75-year-old man had been admitted to another hospital because of left abdominal pain, and was given a diagnosis of left hydronephrosis and acute pancreatitis.
  • US and EUS revealed a chronic pancreatitis-like pattern and multicystic lesion in the pancreas head and body.
  • At that time enhanced CT findings showed an extrapancreatic low density area to be inflammatory change, extending from the pancreas body to the left crus of the diaphragm and posteriorly the spreading from the left crus of the diaphragm via the left urinary duct into the left iliopsoas muscle, in which MRI revealed partial high intensity.
  • ERCP and MRCP showed focal irregular narrowing of the pancreatic duct of unknown cause, and we decided that an internal pancreatic fistula due to pancreatitis had induced left ureteral obstruction, caused by a protein plug or alcohol.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Carcinoma, Pancreatic Ductal / complications. Pancreatic Fistula / complications. Pancreatic Neoplasms / complications. Ureteral Obstruction / etiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675827.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia; 2006 Apr;8(4):279-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.
  • The aim of this study is to examine the Wnt/beta-catenin pathway in patients with advanced pancreatic adenocarcinoma (n = 31).
  • Thus, Wnt/beta-catenin activation was observed in 65% of pancreatic adenocarcinomas, independently of beta-catenin gene mutations in most tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 1999 Nov-Dec;60(6):544-8 [10545724.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):285-302 [16012954.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6776-84 [10597286.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] J Med Invest. 2000 Feb;47(1-2):47-55 [10740979.001]
  • [Cites] Development. 2001 Mar;128(6):871-81 [11222142.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3245-9 [11309273.001]
  • [Cites] Hepatology. 2001 May;33(5):1098-109 [11343237.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):37-52 [11467451.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cancer Lett. 2006 Feb 28;233(2):328-37 [15893416.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1219-32 [11579131.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4127-34 [11911306.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Science. 2002 May 31;296(5573):1644-6 [12040179.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2015-27 [12174879.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Dev Dyn. 2002 Nov;225(3):260-70 [12412008.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):838-43; discussion 844 [12504222.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):202-16 [12512043.001]
  • [Cites] J Pathol. 2003 Feb;199(2):185-90 [12533831.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:199-231 [12195027.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):586-92 [12566300.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):621-5 [12642683.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Hepatology. 2003 Apr;37(4):824-32 [12668975.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):161-70 [12706873.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Trends Cell Biol. 2003 Jun;13(6):328-35 [12791299.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97 [12849999.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1134-46 [15057752.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Trends Genet. 1993 Sep;9(9):317-21 [8236461.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):177-84 [7824270.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):851-8 [9647782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):325-9 [10027390.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):431-6 [10201374.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):504-11 [10404062.001]
  • [Cites] Semin Liver Dis. 1999;19(3):235-42 [10518303.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1253-6 [10523691.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Hepatol. 2005 Jul;43(1):132-41 [15893845.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • (PMID = 16756720.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NIDDK NIH HHS / DK / 1R01DK62277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC1600679
  •  go-up   go-down


49. Abe K, Suda K, Arakawa A, Yamasaki S, Sonoue H, Mitani K, Nobukawa B: Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia. Pancreas; 2007 Jan;34(1):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia.
  • OBJECTIVES: To examine aberrations and differences of cell cycle regulatory proteins between intraductal papillary-mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasias (PanINs).
  • METHODS: In total, 47 IPMN lesions and 42 PanIN lesions were obtained from 26 patients with IPMN and 16 patients who underwent pancreatic surgery for invasive pancreatic ductal cancer or other diseases.
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Pancreatic Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198188.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


50. Okada K, Hirabayashi K, Imaizumi T, Matsuyama M, Yazawa N, Dowaki S, Tobita K, Ohtani Y, Tanaka M, Inokuchi S, Makuuchi H: Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas. Biomed Res; 2010 Feb;31(1):13-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas.
  • Eighty patients that underwent primary resection for pancreatic IPMNs were retrospectively analyzed.
  • Invasive IPMCs were further divided into 12 minimally invasive IPMCs (MI-IPMCs) and 11 invasive carcinomas originating from IPMCs (IC-IPMCs) according to the Japan Pancreatic Society classification.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / biosynthesis. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / metabolism. Thrombospondin 1 / biosynthesis


51. Yango J, Pieters T, Coche E, Lambert M: [Increased serum CA 19.9 in bronchiectasis]. Rev Mal Respir; 2008 Jan;25(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Elévation du CA 19.9 sérique et bronchectasies.
  • INTRODUCTION: CA 19.9 is considered the most specific and sensitive serological marker of pancreatic adenocarcinoma.
  • Exhaustive investigation and clinical evolution excluded a neoplastic digestive disorder but positron emission tomography revealed a distinct hypermetabolic focus in the area of the hilum of the right lung.
  • [MeSH-major] Bronchiectasis / diagnosis. CA-19-9 Antigen / blood
  • [MeSH-minor] Aged. Biomarkers / blood. Female. Haemophilus Infections / diagnosis. Haemophilus Infections / immunology. Haemophilus influenzae / immunology. Haemophilus influenzae / isolation & purification. Humans

  • Genetic Alliance. consumer health - Bronchiectasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288056.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen
  •  go-up   go-down


52. Chen J, Röcken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett; 2006 Feb 28;233(2):328-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
  • Pancreatic cancers express KIT and PDGFRs.
  • Therefore, 26 patients with unresectable pancreatic cancer were randomized to either gemcitabine (1000 mg/m2 weekly) or imatinib (2x400 mg po) treatment daily.
  • Pancreatic adenocarcinoma was confirmed histologically and expression of KIT and PDGFRbeta was determined immunohistochemically in the biopsy specimens.
  • In this small series of pancreatic cancer patients, treatment with imatinib was not associated with a significant control of cancer progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Benzamides. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Humans. Imatinib Mesylate. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Male. Middle Aged. Proto-Oncogene Proteins c-kit / metabolism. Quality of Life. Receptors, Platelet-Derived Growth Factor / metabolism. Surveys and Questionnaires. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893416.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0W860991D6 / Deoxycytidine; 8A1O1M485B / Imatinib Mesylate; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


53. Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA: Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res; 2010 Dec 1;16(23):5712-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
  • PURPOSE: Pancreatic carcinoma is one of the deadliest cancers with few effective treatments.
  • We used the astounding heating rates of AuNPs in nonionizing radiofrequency (RF) radiation to investigate human pancreatic xenograft destruction in a murine model.
  • EXPERIMENTAL DESIGN: Weekly, Panc-1 and Capan-1 human pancreatic carcinoma xenografts in immunocompromised mice were exposed to an RF field 36 hours after treatment (intraperitoneal) with cetuximab- or PAM4 antibody-conjugated AuNPs, respectively.
  • Cetuximab- and PAM4-conjugated AuNPs demonstrated RF field-induced destruction of Panc-1 and Capan-1 pancreatic carcinoma xenografts after 6 weeks of weekly treatment (P = 0.004 and P = 0.035, respectively).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S [14506191.001]
  • [Cites] J Biomed Opt. 2000 Oct;5(4):383-90 [11092426.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 2):2245-51 [445424.001]
  • [Cites] Ann Clin Lab Sci. 1981 Sep-Oct;11(5):386-91 [7036839.001]
  • [Cites] J Urol. 1989 Nov;142(5):1364-8 [2810532.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-9 [2106751.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1271-86 [8863675.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Lasers Surg Med. 1998;23(4):194-203 [9829430.001]
  • [Cites] Langmuir. 2005 Nov 8;21(23):10644-54 [16262332.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S45-53 [16447274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5225-32 [18024868.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2654-65 [17960610.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] Nat Protoc. 2008;3(2):314-20 [18274533.001]
  • [Cites] Biophys J. 2008 May 15;94(10):3790-7 [18234813.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4819-26 [18559529.001]
  • [Cites] Surgery. 2008 Aug;144(2):125-32 [18656617.001]
  • [Cites] J Exp Ther Oncol. 2008;7(4):313-26 [19227011.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):836-47 [19194760.001]
  • [Cites] World J Gastroenterol. 2009 Jun 28;15(24):2995-3002 [19554652.001]
  • [Cites] Small. 2009 Jul;5(13):1553-61 [19326357.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Radiat Biol. 2009 Dec;85(12):1114-25 [19995237.001]
  • [Cites] Adv Drug Deliv Rev. 2010 Mar 8;62(3):339-45 [19909777.001]
  • [Cites] J Surg Oncol. 2010 Mar 15;101(4):315-20 [20187063.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 May 15;245(1):116-23 [20193702.001]
  • [Cites] Cancer. 2010 Jul 1;116(13):3285-93 [20564640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54 [14597719.001]
  • (PMID = 21138869.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA151668-02; United States / NCI NIH HHS / CA / T32 CA09599; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / U54 CA151668; United States / NCI NIH HHS / CA / T32 CA009599-21; United States / NCI NIH HHS / CA / U54 CA143837; United States / NCI NIH HHS / CA / U54CA143837; United States / NCI NIH HHS / CA / U54 CA151668-02; United States / NCI NIH HHS / CA / T32 CA009599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 7440-57-5 / Gold; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS245136; NLM/ PMC3057504
  •  go-up   go-down


54. Mansour JC, Schwartz L, Pandit-Taskar N, D'Angelica M, Fong Y, Larson SM, Brennan MF, Allen PJ: The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg; 2006 Dec;10(10):1354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas.
  • Previous studies have suggested that whole body positron-emission tomography (PET) can distinguish between benign and malignant cysts of the pancreas.
  • Patients were identified (n = 68) who had undergone whole body PET imaging for a cystic lesion of the pancreas between Jan.
  • Within the resected group of patients (n=21), four of the seven patients (57%) with either in situ or invasive malignancy (adenocarcinoma: 3 of 5, papillary mucinous carcinoma: 1 of 2) had positive PET imaging (mean SUV, 5.9; range 2.5-8.0), and 2 of the 14 patients (14%) with benign lesions had positive PET imaging (serous cystadenoma, n=1, SUV=3.3; pseudocyst n=1, SUV=2.7).
  • We do not believe whole body FDG-PET to be essential in the evaluation of cystic lesions of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenocarcinoma, Mucinous / diagnostic imaging. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9 [15623441.001]
  • [Cites] Surgery. 2005 Oct;138(4):672-9; discussion 679-80 [16269296.001]
  • [Cites] Clin Adv Hematol Oncol. 2005 Jun;3(6):461-3 [16167022.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Langenbecks Arch Surg. 1998 Mar;383(1):56-61 [9627172.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):970-7 [14675706.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):675-80 [11685032.001]
  • [Cites] Radiology. 2000 Dec;217(3):757-64 [11110940.001]
  • [Cites] Surgery. 2002 Oct;132(4):628-33; discussion 633-4 [12407346.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):1007-9; discussion 1009 [16530543.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Cancer Treat Rev. 2005 Nov;31(7):507-35 [16257126.001]
  • (PMID = 17175454.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


55. Wada K, Takada T, Amano H, Yoshida M, Miura F, Toyota N, Kato K, Isaka T, Nagashima I: [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe]. Nihon Geka Gakkai Zasshi; 2006 Jul;107(4):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe].
  • Pancreatic adenocarcinoma remains to have poor prognosis.
  • Current rationale for the treatment of pancreatic adenocarcinoma in the US and European countries consists of the following formula:.
  • The efficacy of "Japanese" radical resection including vascular resection or pancreatic nerve plexus resection should be evaluated, although the devise of novel diagnostic modalities and more effective adjuvant or neoadjuvant therapy are crucial to improve prognosis of this disease.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878412.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


56. Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, Klimstra DS, O'Reilly EM: Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol; 2009 Jul 1;100(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center.
  • BACKGROUND: There is a dearth of data in a younger population of patients with pancreatic ductal adenocarcinoma (PAC) regarding epidemiology, genetics, prognosis, and outcome.
  • RESULTS: One hundred thirty-six cases of PAC, age <or=45 years at diagnosis, were identified.
  • [MeSH-major] Adenocarcinoma / mortality. Pancreatic Neoplasms / mortality

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19384918.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Grenacher L, Klauss M: [Computed tomography of pancreatic tumors]. Radiologe; 2009 Feb;49(2):107-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Computed tomography of pancreatic tumors].
  • Computed tomography (CT) and in particular multi-detector row computed tomography (MDCT), also known as multislice CT (MSCT), is ideally suited for detecting pancreatic tumors because of the high spatial resolution.The method of choice is hydro-CT which involves distension of the stomach and duodenum by administration of 1-1.5 l water as a negative contrast medium under medically induced hypotension by administration of buscopan.
  • The patient is laid on the right side at an angle of 30-45 degrees in order to obtain an artefact-free image of the close anatomical relationship around the pancreas head.
  • After the correct diagnosis of an adenocarcinoma has been made only 20% of all patients are shown to have a surgically resectable disease, but the overall survival rate is significantly higher after resection in combination with a multimodal tumor therapy strategy.
  • The reason is that the correct diagnosis of the resectability of the tumor is one of the main criteria for overall survival of these patients.
  • Currently practically all pancreatic tumors can be detected using MDCT and the detection rate varies between 70% and 100% (most recent literature references give a sensitivity of 89% and specificity up to 99%).
  • In some rare cases the differentiation between focal necrotizing pancreatitis and pancreatic carcinoma can be difficult even with sophisticated protocols.
  • MDCT is an ideal tool for the detection of neuroendocrine tumors, metastases and for the differentiation of cystic pancreatic lesions such as pseudocysts, microcystic adenomas or intraductal papillary mucinous neoplasms (IPMN).
  • Particularly, the differentiation of the latter into benign, borderline or malignant transformation is not always possible, but indirect signs, such as small nodules adjacent to the ductal wall, the diameter of the pancreatic duct, or a direct communication between cystic lesions and duct can be detected because of the high spatial resolution and is comparable to the findings in MRI.
  • [MeSH-major] Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Pancreatic Neoplasms / diagnostic imaging. Tomography, Spiral Computed
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / diagnostic imaging. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnostic imaging. Carcinoma, Pancreatic Ductal / mortality. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / diagnostic imaging. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Diagnosis, Differential. Disease-Free Survival. Humans. Neuroendocrine Tumors / diagnostic imaging. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreas / diagnostic imaging. Pancreas / pathology. Pancreatectomy. Pancreatic Pseudocyst / diagnostic imaging. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2006 Nov;79(947):880-7 [16822803.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Pancreatology. 2008;8(3):236-51 [18497542.001]
  • [Cites] Radiologe. 2003 Apr;43(4):293-300 [12721645.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Pancreas. 2005 Apr;30(3):218-22 [15782097.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1471-84 [16284129.001]
  • [Cites] Eur Radiol. 2004 Jul;14 (7):1188-95 [15083335.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Radiology. 2000 Jul;216(1):163-71 [10887243.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):149-56 [12541123.001]
  • [Cites] Radiologe. 2008 Aug;48(8):752-63 [18633589.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):459-64 [9242754.001]
  • [Cites] Eur J Radiol. 2007 Jun;62(3):371-7 [17433598.001]
  • [Cites] Chirurg. 2003 Mar;74(3):202-7 [12647076.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Histopathology. 2008 Apr;52(5):539-51 [17903202.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Radiologe. 1996 May;36(5):397-405 [8778924.001]
  • [Cites] J Magn Reson Imaging. 2007 Jul;26(1):86-93 [17659551.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Apr 13;132(15):813-7 [17427092.001]
  • [Cites] Arch Surg. 1998 Jan;133(1):61-5 [9438761.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):75-85 [16372157.001]
  • [Cites] Pancreatology. 2008;8(2):199-203 [18434757.001]
  • [Cites] Radiology. 2006 Mar;238(3):912-9 [16439566.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1553-9 [16773248.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] Pancreas. 2006 Aug;33(2):111-8 [16868475.001]
  • [Cites] JOP. 2007 Mar 10;8(2):214-22 [17356246.001]
  • [Cites] Pancreatology. 2008;8(2):135-41 [18382099.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1311-23 [12704043.001]
  • [Cites] Pancreatology. 2008;8(2):204-10 [18434758.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Rofo. 1998 Mar;168(3):211-6 [9551105.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] AJR Am J Roentgenol. 1990 Nov;155(5):995-6 [2120971.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] J Gastrointest Surg. 1999 May-Jun;3(3):233-43 [10481116.001]
  • [Cites] Eur Radiol. 2007 Mar;17(3):638-49 [17021700.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1513-20 [17114545.001]
  • [Cites] Pancreatology. 2009;9(5):621-30 [19657217.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Radiology. 1993 Mar;186(3):799-802 [8381551.001]
  • [Cites] Pancreatology. 2001;1(6):648-55 [12120249.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):472-82 [9843608.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19137277.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 71
  •  go-up   go-down


58. Furukawa H, Uesaka K, Boku N: Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography. Arch Surg; 2008 Mar;143(3):275-80; discussion 281
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography.
  • HYPOTHESIS: Multidetector-row computed tomography reduces the frequency of use of other imaging methods in patients with pancreatic carcinoma.
  • PATIENTS: Two hundred thirteen patients with pancreatic carcinoma.
  • MAIN OUTCOME MEASURE: Multidetector-row computed tomography was initially performed in patients with newly diagnosed pancreatic carcinoma.
  • RESULTS: Of the 213 pancreatic carcinomas, 79 (37%) were classified as probably resectable, 127 (60%) as certainly unresectable, and 7 (3%) as probably unresectable.
  • CONCLUSIONS: Multidetector-row computed tomography provides reliable information for staging pancreatic carcinoma.
  • Multidisciplinary team discussion along with use of this noninvasive technique simplifies the diagnostic strategy for pancreatic carcinoma and decreases the need for invasive staging methods.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / radiography. Decision Making. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347275.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R, Lillemoe KD: Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg; 2009 May;208(5):989-94; discussion 994-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer.
  • Clinical and basic studies have shown obesity to be associated with an increased incidence and progression of pancreatic cancer.
  • The precise role that pancreatic fat plays in this process has remained undefined.
  • We tested the hypothesis that pancreatic steatosis would be associated with increased dissemination and reduced survival in patients with resected pancreatic cancer.
  • STUDY DESIGN: A case-control analysis was conducted in patients who had undergone resection for pancreatic adenocarcinoma.
  • Pancreatic neck margins were reviewed in a blinded fashion by two trained investigators.
  • Pancreatic fat (number of cells/5 high power field) and degree of fibrosis (0 to 4+) were recorded.
  • RESULTS: Node-positive patients had significantly more fat cells in the pancreas compared with node-negative patients (46.4 +/- 8.7 versus 21.4 +/- 4.8; p < 0.02).
  • CONCLUSIONS: These data show that increased pancreatic fat promotes dissemination and lethality of pancreatic cancer.
  • We conclude that pancreatic steatosis alters the tumor microenvironment, enhances tumor spread, and contributes to the early demise of patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adipose Tissue / pathology. Pancreas / pathology. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology


60. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD: Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One; 2007 Apr 25;2(4):e392
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells.
  • Emerging evidence indicates the importance of reactivated Wnt signaling in a number of cancers, including pancreatic adenocarcinoma.
  • PRINCIPLE FINDINGS: Both Sulf proteins were upregulated in human pancreatic adenocarcinoma tumors and were broadly expressed in human pancreatic adenocarcinoma cell lines.
  • Three of four pancreatic adenocarcinoma cell lines tested exhibited autocrine Wnt signaling, in that extracellular Wnt ligands were required to initiate downstream Wnt signaling.
  • Exposure of these pancreatic adenocarcinoma cells to a catalytically inactive form of Sulf-2 or siRNA-mediated silencing of endogenous Sulf-2 inhibited both Wnt signaling and cell growth.
  • CONCLUSIONS/SIGNIFICANCE: We have identified the Sulfs as potentiators of autocrine Wnt signaling in pancreatic cancer cells and have demonstrated their contribution to the growth and tumorigenicity of these cells.
  • Since the Sulfs are extracellular enzymes, they would be attractive targets for therapy of pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1439-47 [14973553.001]
  • [Cites] Genes Cells. 2002 Feb;7(2):173-85 [11895481.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7 [15067127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5 [15240889.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6170-4 [15208662.001]
  • [Cites] J Neurosci Res. 2004 Sep 1;77(5):653-61 [15352211.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):497-506 [15542433.001]
  • [Cites] Development. 2004 Dec;131(24):6009-21 [15563523.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):743-8 [15705870.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Mol Ther. 2005 May;11(5):724-33 [15851011.001]
  • [Cites] Mol Cancer. 2005;4(1):14 [15817123.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):459-67 [15905855.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6245-54 [16024626.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):40066-73 [16192265.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):1001-10 [16331886.001]
  • [Cites] Dev Dyn. 2006 Mar;235(3):681-90 [16425220.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4969-76 [16377625.001]
  • [Cites] BMC Biochem. 2006;7:2 [16417632.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2130-44 [16762634.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6025-32 [16778174.001]
  • [Cites] Biochem J. 2006 Nov 15;400(1):63-73 [16901266.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):678-88 [17116694.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):329-32 [10888884.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):169-73 [11457867.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):357-61 [11489926.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30744-52 [11406624.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1663-6 [11533491.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 20;306(1):293-7 [12788103.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):341-51 [12860968.001]
  • [Cites] J Virol. 2003 Aug;77(16):8957-61 [12885912.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):231-48 [14699503.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5604-11 [14645250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • (PMID = 17460759.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075602; United States / NIGMS NIH HHS / GM / GM57411; United States / NIGMS NIH HHS / GM / R01 GM057411; United States / NCI NIH HHS / CA / R21 CA122025; United States / NCI NIH HHS / CA / R01 CA112537; United States / NHLBI NIH HHS / HL / HL075602; United States / NCI NIH HHS / CA / CA122025; United States / NCI NIH HHS / CA / CA112537
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; EC 3.1.6.- / Sulfatases
  • [Other-IDs] NLM/ PMC1849966
  • [General-notes] NLM/ Original DateCompleted: 20070803
  •  go-up   go-down


61. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol; 2006 Aug 20;24(24):3946-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
  • PURPOSE: To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic pancreatic cancer.
  • PATIENTS AND METHODS: Patients with advanced adenocarcinoma of the pancreas were randomly assigned to receive either gemcitabine 1,000 mg/m2 and cisplatin 50 mg/m2 given on days 1 and 15 of a 4-week cycle (GemCis arm) or gemcitabine alone at a dose of 1,000 mg/m2 on days 1, 8, and 15 of a 4-week regimen (Gem arm).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 20;25(9):1142; author reply 1142-3 [17369580.001]
  • (PMID = 16921047.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Zhu JS, Song MQ, Chen GQ, Li Q, Sun Q, Zhang Q: Molecular mechanisms of paclitaxel and NM-3 on human gastric cancer in a severe combined immune deficiency mice orthotopic implantation model. World J Gastroenterol; 2007 Aug 14;13(30):4131-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Isocoumarins / pharmacology. Paclitaxel / pharmacology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696236.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Antineoplastic Agents; 0 / Isocoumarins; 0 / Viral Core Proteins; 0 / isocoumarin NM-3; 0 / p27 antigen, Mouse mammary tumor virus; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC4205319
  •  go-up   go-down


63. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ: Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem; 2008 Oct;54(10):1716-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues.
  • The aim of this study was to determine, as a proof of principle, whether specific candidate miRNAs could be detected in fine-needle aspirate (FNA) biopsies of pancreatic ductal adenocarcinoma (PDAC) and could accurately differentiate malignant from benign pancreatic tissues.
  • METHODS: We used TaqMan(R) assays to quantify miRNA levels in FNA samples collected in RNARetain (n = 16) and compared the results with a training set consisting of frozen macrodissected pancreatic samples (n = 20).
  • RESULTS: Quantitative reverse-transcription PCR analysis confirmed that miRNA levels are affected in PDAC FNAs and correlate well with the changes observed in the training set of frozen pancreatic samples.
  • CONCLUSIONS: To the best of our knowledge, this study is the first to evaluate the diagnostic potential of miRNAs in a clinical setting and has shown that miRNA analysis of pancreatic FNA biopsy samples can aid in the pathologic evaluation of suspicious cases and may provide a new strategy for improving the diagnosis of pancreatic diseases.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):470-4 [11275888.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Dig Dis. 2001;19(1):32-6 [11385249.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3581-6 [12097256.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1647-53 [12324479.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2960-71 [12784330.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5980-7 [14676123.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Cancer. 2004 Aug 25;102(4):239-46 [15368316.001]
  • [Cites] Nucleic Acids Res. 2004;32(16):e131 [15371555.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1384-90 [15316565.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):198-203 [8157358.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):953-64 [7657125.001]
  • [Cites] Gastrointest Endosc. 1997 May;45(5):387-93 [9165320.001]
  • [Cites] Gastrointest Endosc. 1997 Nov;46(5):417-23 [9402115.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3 [10367874.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2213-36 [16146690.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):119-26 [16441422.001]
  • [Cites] Pancreas. 2006 Mar;32(2):171-7 [16552337.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):754-9 [16723855.001]
  • [Cites] World J Gastroenterol. 2006 Jun 7;12(21):3344-51 [16733850.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Nov;21(11):1646-55 [16984583.001]
  • [Cites] World J Gastroenterol. 2007 Jan 14;13(2):257-63 [17226905.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):457-63 [17224927.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2344-52 [17311258.001]
  • [Cites] Pancreas. 2007 May;34(4):436-43 [17446843.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] RNA. 2007 Oct;13(10):1668-74 [17698639.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):203-11 [18403610.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • (PMID = 18719196.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075059; United States / NCI NIH HHS / CA / R21 CA133715; United States / NCI NIH HHS / CA / CA-133715
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS517274; NLM/ PMC4040292
  •  go-up   go-down


64. Fukushima N, Fukayama M: Mucinous cystic neoplasms of the pancreas: pathology and molecular genetics. J Hepatobiliary Pancreat Surg; 2007;14(3):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystic neoplasms of the pancreas: pathology and molecular genetics.
  • Mucinous cystic neoplasm (MCN) of the pancreas is a distinct clinicopathological entity characterized by mucin-producing epithelial and cyst-forming neoplasm with "ovarian-type" stroma beneath the epithelial component.
  • It is clearly distinguished from ductal adenocarcinoma and intraductal papillary mucinous neoplasm (IPMN).
  • However, MCN can progress to infiltrating carcinoma, and frequently shows a similar histological pattern to ductal adenocarcinoma.
  • Several genetic alterations such as K-ras oncogene mutation, and epigenetic alterations such as hypermethylation of p16 in the invasive component of MCN are also common with ductal adenocarcinoma.
  • MCN is one of the precursors of invasive pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520198.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 24
  •  go-up   go-down


65. Nakakura EK, Bergsland EK: Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am; 2007 Jun;21(3):457-73; viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
  • In contrast with patients who have adenocarcinoma of the pancreas, those who have islet cell carcinomas can achieve long-term survival even if their disease is advanced.
  • [MeSH-major] Carcinoma, Islet Cell. Common Bile Duct Neoplasms. Neuroendocrine Tumors. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548034.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


66. Goh BK, Loh HL, Soo KC: Synchronous pancreatic serous cystic tumor, intraductal papillary mucinous tumor and gastric carcinoma: report of a case. Pancreas; 2005 Aug;31(2):195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous pancreatic serous cystic tumor, intraductal papillary mucinous tumor and gastric carcinoma: report of a case.
  • Synchronous cystic tumors of the pancreas are rarely reported in the literature.
  • We report an unusual case of synchronous pancreatic serous cystic tumor (SCT) and intraductal pancreatic mucinous tumor (IPMT) with concomitant gastric carcinoma.
  • This study highlights the importance of careful intra-operative and pathologic examination for concomitant pancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025009.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Kanda M, Fujii T, Sahin TT, Kanzaki A, Nagai S, Yamada S, Sugimoto H, Nomoto S, Takeda S, Kodera Y, Morita S, Nakao A: Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. Ann Surg; 2010 Mar;251(3):483-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas.
  • OBJECTIVES: A retrospective study was performed to determine the prognostic implications of invasion to the splenic vessels in pancreatic body and tail cancer.
  • SUMMARY BACKGROUND DATA: Involvement of the splenic artery (SA) and vein (SV) is frequently observed in carcinoma of the body and tail of the pancreas, but its correlation with various other clinicopathologic factors and prognosis has not been explored in detail.
  • METHODS: Fifty-one patients who had undergone distal pancreatectomy for invasive adenocarcinoma of the body and tail of the pancreas were discreetly selected from the prospective data base for analyses.
  • CONCLUSIONS: Our results indicated that the invasion of the SA, but not that of the SV, is a crucial prognostic factor in pancreatic body and tail cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology. Splenic Artery. Vascular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20101172.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Trivedi PJ, Gupta P, Phillips-Hughes J, Ellis A: Biloma: an unusual complication in a patient with pancreatic cancer. World J Gastroenterol; 2009 Nov 7;15(41):5218-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biloma: an unusual complication in a patient with pancreatic cancer.
  • We report the case of a 64-year-old man initially diagnosed with a non-obstructive malignancy of the pancreas, who developed a spontaneous intrahepatic biloma 8 mo later.
  • We believe this is the first documented case of spontaneous intrahepatic biloma to occur secondary to pancreatic malignancy.
  • [MeSH-major] Adenocarcinoma / complications. Bile / metabolism. Bile Duct Diseases / etiology. Bile Duct Diseases / metabolism. Bile Ducts, Intrahepatic / metabolism. Pancreatic Neoplasms / complications

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 The WJG Press and Baishideng. All rights reserved.
  • [Cites] Arch Surg. 2004 Oct;139(10):1083-7 [15492148.001]
  • [Cites] Br J Surg. 1971 Jan;58(1):38-42 [5539240.001]
  • [Cites] Surgery. 1974 May;75(5):664-73 [4824426.001]
  • [Cites] AJR Am J Roentgenol. 1979 Jun;132(6):1014-5 [108953.001]
  • [Cites] Am J Gastroenterol. 1998 Nov;93(11):2282-4 [9820416.001]
  • [Cites] Gastroenterology. 1984 Apr;86(4):743-4 [6698374.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):933-8 [3885693.001]
  • [Cites] Am J Gastroenterol. 1993 Dec;88(12):2117-8 [8249987.001]
  • [Cites] Gastrointest Radiol. 1983;8(3):237-43 [6618090.001]
  • (PMID = 19891023.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2773903
  •  go-up   go-down


69. Sanchez SE, Trevino JG: Current adjuvant and targeted therapies for pancreatic adenocarcinoma. Curr Med Chem; 2008;15(17):1674-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current adjuvant and targeted therapies for pancreatic adenocarcinoma.
  • Pancreatic cancer is one of the deadliest malignancies, costing the lives of more than 30,000 patients every year.
  • Gemcitabine is currently considered to be the standard of care for the treatment of advanced pancreatic cancer.
  • In this paper we present an overview of the current treatment options for the different presenting stages of pancreatic cancer, including adjuvant, neoadjuvant, and targeted therapies, and attempt to provide a comprehensive analysis of the disparate research indicated on this front.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adjuvants, Pharmaceutic / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673217.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic
  • [Number-of-references] 76
  •  go-up   go-down


70. Ujiki MB, Talamonti MS: Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol; 2007 Aug;34(4):311-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the surgical management of pancreatic adenocarcinoma.
  • Despite these advances, morbidity and mortality after pancreaticoduodenectomy are not insignificant and the overall prognosis following resection for adenocarcinoma of the pancreas remains poor.
  • This article will attempt to describe current guidelines for the preoperative, intraoperative, and postoperative management of patients with localized pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674959.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


71. Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Büchler MW, Friess H: The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg; 2006 Aug;244(2):274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neurotrophic factor artemin promotes pancreatic cancer invasion.
  • OBJECTIVE: To analyze the role of Artemin in pancreatic ductal adenocarcinoma (PDAC) in terms of expression, influence on cancer cell behavior, and pain correlation.
  • METHODS: Artemin and its receptors (GFRalpha3/RET) were studied in PDAC tissues and normal pancreas by Western blot analysis and immunohistochemistry.
  • RNA expression was analyzed in pancreatic tissues (normal, cancer) and pancreatic cancer cell lines by QRT-PCR.
  • RESULTS: Artemin and GFRalpha3/RET were both detected at enhanced levels in PDAC compared with normal pancreas, localizing predominantly in hypertrophic nerves and arterial walls, as well as in cancer cells of primary and metastatic lesions.
  • However, Artemin promoted pancreatic cancer cell invasion up to 5-fold, without affecting cancer cell proliferation.
  • However by increasing cancer cell invasion, Artemin seems to influence neural invasion and thereby contribute to cancer cell spreading along pancreatic nerves.
  • [MeSH-major] Adenocarcinoma / pathology. Nerve Growth Factors / physiology. Nerve Tissue Proteins / physiology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Proliferation. Coloring Agents. Glial Cell Line-Derived Neurotrophic Factor Receptors / physiology. Humans. Hypertrophy. Immunohistochemistry. Neoplasm Invasiveness. Nerve Regeneration / physiology. Neurons / pathology. Pain / physiopathology. Pancreas / innervation. Pancreas / pathology. Polymerase Chain Reaction. Prospective Studies. Tetrazolium Salts. Thiazoles

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2003 Aug;27(2):190-6 [12883269.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):144-51 [15622002.001]
  • [Cites] Nat Med. 2003 Nov;9(11):1383-9 [14528299.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):71-81 [14712212.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5291-300 [15289335.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Ann Surg. 1989 Feb;209(2):181-7 [2464969.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):529-36 [1985049.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Science. 1993 May 21;260(5111):1130-2 [8493557.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):219-30 [8020665.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):467-70 [8945474.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3502-8 [9452475.001]
  • [Cites] J Neurosci. 1999 Nov 1;19(21):9322-31 [10531437.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3412-20 [10652334.001]
  • [Cites] Development. 2000 Oct;127(20):4335-44 [11003834.001]
  • [Cites] Pancreas. 2001 Apr;22(3):279-84 [11291930.001]
  • [Cites] Eur J Neurosci. 2001 Jun;13(11):2177-82 [11422460.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):361-73 [11544105.001]
  • [Cites] Development. 2001 Oct;128(19):3685-95 [11585795.001]
  • [Cites] Development. 2001 Oct;128(20):3963-74 [11641220.001]
  • [Cites] Pancreas. 2002 Jan;24(1):15-25 [11741178.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):1991-9 [11713247.001]
  • [Cites] Neuron. 2002 Jul 18;35(2):267-82 [12160745.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Nat Med. 2003 May;9(5):589-95 [12669033.001]
  • [Cites] Neuron. 1998 Feb;20(2):245-53 [9491986.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5801-6 [9576965.001]
  • [Cites] J Am Coll Surg. 1998 Jun;186(6):675-82 [9632157.001]
  • [Cites] J Neurol. 1998 Nov;245(11 Suppl 3):P35-42 [9808338.001]
  • [Cites] Neuron. 1998 Dec;21(6):1291-302 [9883723.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):67-73 [10077155.001]
  • [Cites] Surgery. 2003 Aug;134(2):293-9 [12947332.001]
  • (PMID = 16858191.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARTN protein, human; 0 / Coloring Agents; 0 / Glial Cell Line-Derived Neurotrophic Factor Receptors; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue
  • [Other-IDs] NLM/ PMC1602177
  •  go-up   go-down


72. Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, Masui T, Kawaguchi Y, Tomita K, Oishi S, Fujii N, Uemoto S: Prognostic value of metastin expression in human pancreatic cancer. J Exp Clin Cancer Res; 2009;28:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of metastin expression in human pancreatic cancer.
  • METHODS: We investigated the clinical significance of metastin and GPR54 expression in pancreatic cancer.
  • We evaluated immunohistochemical expression of metastin and GPR54 in pancreatic ductal adenocarcinoma tissues obtained from 53 consecutive patients who underwent resection between July 2003 and May 2007 at Kyoto University Hospital.
  • Metastin expression by pancreatic cancer was an independent prognostic factor for longer survival (hazard ratio, 2.1; 95% confidence interval, 1.1-4.7; p = 0.03), and the patients with a high plasma metastin level (n = 6) did not die after surgical resection.
  • CONCLUSION: Strong expression of metastin and GPR54 by pancreatic cancer is associated with longer survival.
  • Metastin expression is an independent prognostic factor for the survival of pancreatic cancer patients.
  • The plasma metastin level could become a noninvasive prognostic factor for the assessment of pancreatic cancer.
  • [MeSH-major] Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Health. Humans. Immunohistochemistry. Kisspeptins. Male. Middle Aged. Pancreas / metabolism. Prognosis. Receptors, G-Protein-Coupled / metabolism. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Kyoto University Research Information Repository - Articles. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2007 Feb;450(2):143-9 [17216189.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1452-9 [17442564.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(5):874-91 [18280770.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2080-5 [10950061.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1164-72 [11060311.001]
  • [Cites] Nature. 2001 May 31;411(6837):613-7 [11385580.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28969-75 [11387329.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34631-6 [11457843.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7422-5 [11606374.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2399 [11994395.001]
  • [Cites] Oncology. 2002;62(3):251-8 [12065873.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5399-404 [12359743.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):609-17 [12547718.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):11-8 [12650602.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Sep;129(9):531-5 [12898236.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1379-83 [14977840.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 27;315(1):85-92 [15013429.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1319-28 [15020672.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):868-72 [15300798.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7 [8944003.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2384-7 [9192814.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):642-50 [9477095.001]
  • [Cites] Genomics. 1998 Nov 15;54(1):145-8 [9806840.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Bioorg Med Chem Lett. 2006 Jan 1;16(1):134-7 [16242330.001]
  • [Cites] Clin Exp Metastasis. 2005;22(6):503-11 [16320113.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Mar;8(1):41-6 [17323132.001]
  • [Cites] J Pept Sci. 2007 Jun;13(6):422-9 [17486693.001]
  • [Cites] Br J Pharmacol. 2007 Aug;151(8):1143-53 [17519946.001]
  • (PMID = 19154616.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KISS1 protein, human; 0 / KISS1R protein, human; 0 / Kisspeptins; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2639538
  •  go-up   go-down


73. Legoffic A, Calvo E, Cano C, Folch-Puy E, Barthet M, Delpero JR, Ferrés-Masó M, Dagorn JC, Closa D, Iovanna J: The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target. PLoS One; 2009;4(10):e7495
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.
  • BACKGROUND: The aim of our work was to identify the genes specifically altered in pancreatic adenocarcinoma and especially those that are altered early in cancer development.
  • METHODOLOGY/PRINCIPAL FINDINGS: Gene copy number was systematically assessed with an ultra-high resolution CGH oligonucleotide microarray in DNA from samples of pancreatic cancer.
  • The relationship betweena gain in reg4 gene copy number and cancer development was investigated on the human pancreatic cancer cell line Mia-PaCa2 xenografted under the skin of nude mice.
  • CONCLUSIONS/SIGNIFICANCE: It was concluded that adjuvant therapies targeting reg4 could improve the standard treatment of pancreatic cancer with gemcitabine.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Lectins, C-Type / biosynthesis. Lectins, C-Type / genetics. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism


74. Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS: Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg; 2007 Oct;205(4):558-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
  • BACKGROUND: The American Joint Committee on Cancer (AJCC) 6(th) edition staging system for pancreatic adenocarcinoma specifically excludes pancreatic neuroendocrine tumors (PNETs), and a widely accepted staging classification does not exist.
  • Our objective was to evaluate the feasibility of applying the AJCC pancreatic adenocarcinoma staging system to PNETs.
  • When comparing outcomes to those of patients with pancreatic adenocarcinoma, the estimated median survival was significantly better for resected patients with PNETs (60 versus 13 months, p < 0.0001).
  • CONCLUSIONS: When applied to PNETs, the AJCC staging system for pancreatic adenocarcinoma provides survival discrimination by stage for surgical and nonsurgical patients.
  • Survival rates are better for PNETs than for pancreatic adenocarcinoma, but the staging system can effectively stratify patients with PNETs.
  • [MeSH-major] Neoplasm Staging. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903729.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Smith A, Kressley A, Saif MW: Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP; 2009;10(2):212-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Bone Density Conservation Agents / adverse effects. Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Humans. Male. Middle Aged. Neoplasm Staging. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology


76. Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H, Chang CC, Ho EK, Colovai AI, Kaufman H, D'Agati VD, Thaker HM, Remotti H, Galluzzo S, Cinti P, Rabitti C, Allendorf J, Chabot J, Caricato M, Coppola R, Berloco P, Cortesini R: Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol; 2007 Jun 1;178(11):7432-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, we found that patients with melanoma, and carcinomas of the colon, rectum, and pancreas produce the soluble ILT3 protein, which induces the differentiation of CD8(+) T suppressor cells and impairs T cell responses in MLC.
  • [MeSH-major] Adenocarcinoma / immunology. Colorectal Neoplasms / immunology. Graft Rejection / immunology. Graft Rejection / prevention & control. Melanoma / immunology. Pancreatic Neoplasms / immunology. Receptors, Cell Surface / physiology. T-Lymphocytes, Regulatory / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513794.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI55234-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LILRB4 protein, human; 0 / Membrane Proteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


77. Heukamp I, Kilian M, Gregor JI, Kiewert C, Schimke I, Kristiansen G, Walz MK, Jacobi CA, Wenger FA: Impact of polyunsaturated fatty acids on hepato-pancreatic prostaglandin and leukotriene concentration in ductal pancreatic cancer -- is there a correlation to tumour growth and liver metastasis? Prostaglandins Leukot Essent Fatty Acids; 2006 Apr;74(4):223-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of polyunsaturated fatty acids on hepato-pancreatic prostaglandin and leukotriene concentration in ductal pancreatic cancer -- is there a correlation to tumour growth and liver metastasis?
  • Thus we investigated the effects of n-3, n-6 and n-9 PUFAs on tumour growth, liver metastasis and concentration of prostaglandins (PG) and leukotrienes (LT) in experimental ductal pancreatic adenocarcinoma.
  • 4-6 weekly received subcutaneous injections of 10mg N-nitrosobis-2-oxypropylamine (BOP)/kg body weight for 12 weeks in order to induce ductal pancreatic adenocarcinoma.
  • After 32 weeks all animals were sacrificed and pancreas as well as liver were analysed histologically.
  • Furthermore pancreatic and hepatic concentrations of prostaglandins (PGF1alpha, PGE(2)) and LT were measured.
  • FISH-OIL decreased number of macroscopically visible pancreatic tumours (Gr.
  • Furthermore concentration of PGF(1)(alpha), PGE(2) and LT were significantly increased in pancreatic carcinoma compared to tumour-free tissue.
  • 5. FISH-OIL decreased number of visible pancreatic tumours and incidence of histological proven liver metastasis.
  • [MeSH-major] Fatty Acids, Unsaturated / pharmacology. Leukotrienes / metabolism. Liver / metabolism. Liver Neoplasms / secondary. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Prostaglandins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Cricetinae. Dietary Fats, Unsaturated / metabolism. Dietary Fats, Unsaturated / pharmacology. Dinoprost / chemistry. Dinoprost / metabolism. Dinoprostone / chemistry. Dinoprostone / metabolism. Male. Pancreas / cytology. Pancreas / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556492.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Dietary Fats, Unsaturated; 0 / Fatty Acids, Unsaturated; 0 / Leukotrienes; 0 / Prostaglandins; B7IN85G1HY / Dinoprost; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


78. Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee Iii KK, Hughes SJ, Sanders MK, Young JL, Moser AJ: Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford); 2009 Nov;11(7):606-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.
  • BACKGROUND: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is a margin negative (R0) resection.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495714.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2785957
  •  go-up   go-down


79. Caricato M, Borzomati D, Ausania F, Garberini A, Rabitti C, Tonini G, Coppola R: Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology; 2006;6(4):306-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar metastasis from pancreatic adenocarcinoma. A case report.
  • The first discovery of a cerebellar metastasis of pancreatic carcinoma in a living patient is described.
  • Two years earlier the patient had undergone a pancreaticoduodenectomy for an adenocarcinoma of the head of the pancreas with a lymph node metastasis.
  • Clinical evaluation revealed an intracranial tumor without signs of pancreatic recurrence.
  • [MeSH-major] Adenocarcinoma / secondary. Cerebellar Neoplasms / radiography. Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel and IAP.
  • (PMID = 16636605.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


80. Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O: Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. Ultraschall Med; 2010 Dec;31(6):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses.
  • PURPOSE: Contrast-enhanced harmonic endoscopic ultrasonography (CEH-EUS) for the assessment of microcirculation and the delineation of pancreatic tumors in order to characterize and stage them has only recently become available for commercial use, and few reports have been published.
  • The purpose of the study was the qualitative and quantitative digital image analysis of pancreatic adenocarcinomas using conventional endoscopic ultrasonography (EUS) and CEH-EUS and the evaluation of whether contrast medium injection modified adenocarcinoma staging and patient management.
  • MATERIALS AND METHODS: In each of 30 prospectively examined patients with suspected pancreatic solid lesions, CEH-EUS was performed using the same quantity of the contrast agent SonoVue and a low mechanical index (0.3 - 0.4), followed by EUS-FNA.
  • The histology, based on EUS-FNA or surgery and 9 months of follow-up, was: pancreatic adenocarcinoma (n = 15), pseudotumoral chronic pancreatitis (n = 12), neuroendocrine tumor (n = 1), common bile duct tumor (n = 1), lymph node metastases of gastric cancer (n = 1).
  • RESULTS: CEH-EUS showed a hypoenhanced pattern in 14 cases of adenocarcinoma and in 10 cases of chronic pancreatitis.
  • The index of the contrast uptake ratio was significantly lower in adenocarcinoma than in mass-forming chronic pancreatitis.
  • A cut-off uptake ratio index value of 0.17 for diagnosing adenocarcinoma corresponded to an AUC (CI 95%) of 0.86 (0.67 - 1.00) with a sensitivity of 80%, a specificity of 91.7%, a positive predictive value of 92.8%, and a negative predictive value of 78%.
  • The size of the pancreatic mass was assessed significantly more effectively by CEH-EUS but adenocarcinoma staging was not modified.
  • CONCLUSION: The majority of cases of both pancreatic adenocarcinoma and chronic pancreatitis were hypoenhanced and visual discrimination was not possible.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography / methods. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Pancreatic Neoplasms / ultrasonography. Tumor Burden / physiology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Microvessels / ultrasonography. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / ultrasonography. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Phospholipids. Prospective Studies. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21080306.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


81. Nagatomo A, Abe N, Takeuchi H, Yanagida O, Masaki T, Mori T, Sugiyama M, Ohkura Y, Fujioka Y, Atomi Y: Microscopic cancer cell spread in gastric cancer: whole-section analysis of mesogastrium. Langenbecks Arch Surg; 2009 Jul;394(4):655-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2755-7 [7872713.001]
  • [Cites] Am J Surg. 2005 Sep;190(3):496-503 [16105543.001]
  • [Cites] J Surg Oncol. 2000 Nov;75(3):165-71 [11088047.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1193-9 [16938525.001]
  • [Cites] Surg Today. 1997;27(7):617-22 [9306563.001]
  • [Cites] J Clin Pathol. 1994 Oct;47(10):920-3 [7962605.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):369-73 [16392106.001]
  • [Cites] Pancreas. 2006 Jan;32(1):62-6 [16340746.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1255-7 [12218087.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):55-61 [9510311.001]
  • [Cites] Surgery. 2004 Mar;135(3):266-72 [14976476.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1258-62 [10506712.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2268-72 [9404704.001]
  • [Cites] J Surg Oncol. 1997 Jan;64(1):12-6 [9040794.001]
  • [Cites] Gastric Cancer. 2001;4(3):150-5 [11760081.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):452-6 [8422638.001]
  • [Cites] Am Surg. 2003 Jul;69(7):573-7 [12889619.001]
  • [Cites] Surgery. 2005 May;137(5):511-7 [15855922.001]
  • (PMID = 18931855.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Eltoum IA, Eloubeidi MA, Chhieng DC, Tamhane A, Crowe R, Jhala D, St John KD, Wilcox CM, Siegal GP, Vickers S, Jhala NC: Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma. Am J Clin Pathol; 2005 Nov;124(5):697-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma.
  • Our objectives were to devise a cytologic grading system and determine whether it would predict survival of patients with solid-type pancreatic adenocarcinoma.
  • We devised a grading system that independently predicted survival in patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203289.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Azure Stains; 0 / Romanowsky-Giemsa stain; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


83. Bersch VP, Osvaldt AB, Edelweiss MI, Schumacher Rde C, Wendt LR, Abreu LP, Blom CB, Abreu GP, Costa L, Piccinini P, Rohde L: Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice. Pancreas; 2009 Jan;38(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice.
  • OBJECTIVES: To evaluate the effects of nicotine and cigarette smoke exposure on mice submitted to 7,12-dimethylbenzanthracene (DMBA) model of pancreatic carcinogenesis.
  • At day 16, 1 mg of DMBA crystals was implanted in the pancreatic head of both groups.
  • The specimens were evaluated according to the following criteria: normal ducts, reactive hyperplasia, pancreatic intraepithelial neoplasm 3 (PanIN-3), and carcinoma.
  • Pancreatic adenocarcinoma has a higher frequency in the DMBA-n group (14 [51.9%]) than in the DMBA-e (4 [16.7%]) and DMBA-s (4, 13.3%) groups.
  • CONCLUSIONS: Nicotine but not cigarette smoke promotes pancreatic DMBA carcinogenesis in mice.
  • Pancreatic adenocarcinomas and PanINs have the same phenotypic appearance as those that occur in humans.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinogens / toxicity. Carcinoma in Situ / etiology. Nicotine / toxicity. Pancreatic Neoplasms / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. NICOTINE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824948.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


84. Nakata K, Nagai E, Ohuchida K, Hayashi A, Miyasaka Y, Aishima S, Oda Y, Mizumoto K, Tanaka M, Tsuneyoshi M: S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum Pathol; 2010 Jun;41(6):824-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms of the pancreas are subclassified based on morphological features, and different immunohistochemical profiles have been identified in association with the subtypes.
  • We previously reported that S100P was an early developmental marker of pancreatic carcinogenesis and that there was higher S100P expression in intraductal papillary mucinous neoplasms than in normal pancreatic ductal epithelium.
  • S100P expression was not detected in normal pancreatic ductal epithelium but was detected in all intraductal papillary mucinous neoplasm cells (100%) with diffuse nuclear or nuclear/cytoplasmic staining.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / biosynthesis. Calcium-Binding Proteins / biosynthesis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin 5AC / biosynthesis. Mucin-1 / biosynthesis. Mucin-2 / biosynthesis. Neoplasm Invasiveness. Pancreas / metabolism. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20153506.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Neoplasm Proteins; 0 / S100P protein, human
  •  go-up   go-down


85. Alwaheeb S, Chetty R: Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells. J Clin Pathol; 2005 Sep;58(9):987-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells.
  • Imaging of the abdomen showed a mass in the region of the head of the pancreas.
  • Histological evaluation of the pancreatic tumour showed an adenosquamous carcinoma (predominantly composed of squamous carcinoma), which was extensively infiltrative with perineural invasion and involvement of peripancreatic lymph nodes.
  • Areas of pancreatic intraepithelial neoplasia grade III and merging of the squamous and adenocarcinoma components were evident.
  • Although an acantholytic pattern has been noted in squamous carcinomas in other sites, this is the first report of such a pattern in an adenosquamous carcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Giant Cells / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] JOP. 2004 Jul;5(4):220-4 [15254351.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] J Surg Oncol. 1980;14(3):261-5 [7392648.001]
  • [Cites] Gastroenterology. 1982 Dec;83(6):1297-9 [7129033.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Gan No Rinsho. 1990 May;36(6):728-32 [2348561.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):618-22 [1864595.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathology. 1993 Oct;25(4):420-2 [8165013.001]
  • [Cites] Int J Pancreatol. 1995 Oct;18(2):169-75 [8530833.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Pathol Res Pract. 1998;194(8):587-94; discussion 595 [9779494.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Pathol Int. 2000 Jul;50(7):562-7 [10886741.001]
  • (PMID = 16126885.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770836
  •  go-up   go-down


86. Menon R, Zhang Q, Zhang Y, Fermin D, Bardeesy N, DePinho RA, Lu C, Hanash SM, Omenn GS, States DJ: Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer. Cancer Res; 2009 Jan 1;69(1):300-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer.
  • To assess the potential of tumor-associated, alternatively spliced gene products as a source of biomarkers in biological fluids, we have analyzed a large data set of mass spectra derived from the plasma proteome of a mouse model of human pancreatic ductal adenocarcinoma.
  • All seven novel peptides were successfully amplified in pancreas specimens from both wild-type and mutant mice.
  • Our results show that, in a mouse model for human pancreatic cancer, novel and differentially expressed alternative splice isoforms are detectable in plasma and may be a source of candidate biomarkers.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 2006 Aug;88(2):173-84 [16713170.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D75-9 [15608289.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):135-41 [15660109.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):963-5 [15709159.001]
  • [Cites] Genome Res. 2005 Apr;15(4):566-76 [15805497.001]
  • [Cites] Mol Cell Proteomics. 2005 May;4(5):618-25 [15703445.001]
  • [Cites] Genome Res. 2005 Aug;15(8):1118-26 [16077011.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):157-71 [16215274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 [16585505.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):339-45 [16778561.001]
  • [Cites] Genome Biol. 2006;7(4):R35 [16646984.001]
  • [Cites] JAMA. 2000 May 17;283(19):2552-8 [10815119.001]
  • [Cites] Cytogenet Cell Genet. 2000;90(3-4):291-7 [11124536.001]
  • [Cites] Science. 2001 May 4;292(5518):929-34 [11340206.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):946-51 [11581660.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Dec;2(6):709-35 [12503217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3107-12 [12626741.001]
  • [Cites] Bioinformatics. 2003;19 Suppl 1:i315-22 [12855476.001]
  • [Cites] Clin Exp Metastasis. 2003;20(6):499-505 [14598883.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2502-4 [14668247.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):71-81 [14712212.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1466-7 [14976030.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W20-5 [15215342.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1149-55 [15387337.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5616-9 [3664468.001]
  • [Cites] Cancer Res. 1988 Nov 15;48(22):6354-9 [3180054.001]
  • [Cites] J Proteome Res. 2006 Aug;5(8):2009-18 [16889424.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 15;170(2):147-51 [17011986.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1948-55 [17035404.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):1011-9 [17096071.001]
  • [Cites] Pancreas. 2007 Aug;35(2):114-9 [17632316.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1331-42 [17496331.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):657-63 [18245464.001]
  • [Cites] Nature. 2008 Mar 13;452(7184):181-6 [18337815.001]
  • [Cites] Nature. 2008 Mar 13;452(7184):230-3 [18337823.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):571-9 [18385731.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2008 May;40(5):426-36 [18465028.001]
  • [Cites] PLoS Med. 2008 Jun 10;5(6):e123 [18547137.001]
  • [Cites] Mol Cell Proteomics. 2008 Jul;7(7):1214-24 [18353764.001]
  • [Cites] Mol Cell. 2008 Jul 25;31(2):190-200 [18657502.001]
  • [Cites] Eur J Surg. 1993 Feb;159(2):101-7 [8098623.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3615-8 [8631970.001]
  • [Cites] Genomics. 1998 Feb 1;47(3):327-40 [9480746.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1720-30 [10022859.001]
  • [Cites] FEBS Lett. 2005 Jan 31;579(3):690-8 [15670830.001]
  • (PMID = 19118015.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084982; United States / NLM NIH HHS / LM / R01 LM008106; United States / NCI NIH HHS / CA / U01 CA084313; United States / NLM NIH HHS / LM / R01 LM008106-04; United States / NCI NIH HHS / CA / U01 CA084313-10; United States / NCI NIH HHS / CA / CA117969-01; United States / NCI NIH HHS / CA / P01 CA117969; United States / NLM NIH HHS / LM / R01 LM 008106; United States / NCI NIH HHS / CA / P01 CA117969-01; United States / NIDA NIH HHS / DA / DA021519-04; United States / NCRR NIH HHS / RR / P41 RR018627-020013; United States / NLM NIH HHS / LM / LM008106-04; United States / NCI NIH HHS / CA / U01 CA084982-10; United States / NCRR NIH HHS / RR / RR018627-05; United States / NCRR NIH HHS / RR / P41 RR018627-05; United States / NCI NIH HHS / CA / U01 CA 84313; United States / NCI NIH HHS / CA / CA084982-10; United States / NCI NIH HHS / CA / CA084313-10; United States / NCRR NIH HHS / RR / P41 RR 018627; United States / NIDA NIH HHS / DA / U54 DA021519-04; United States / NIDA NIH HHS / DA / U54 DA 021519; United States / NCI NIH HHS / CO / N01 CO012400; United States / NCI NIH HHS / CA / N01CO12400; United States / NIDA NIH HHS / DA / U54 DA021519; United States / NCRR NIH HHS / RR / P41 RR018627; United States / NCI NIH HHS / CA / 1P01 CA 117969-01; United States / NCRR NIH HHS / RR / RR018627-020013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  • [Other-IDs] NLM/ NIHMS76048; NLM/ PMC2613545
  •  go-up   go-down


87. Hruban RH, Maitra A, Kern SE, Goggins M: Precursors to pancreatic cancer. Gastroenterol Clin North Am; 2007 Dec;36(4):831-49, vi
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors to pancreatic cancer.
  • Infiltrating ductal adenocarcinoma of the pancreas is believed to arise from morphologically distinct noninvasive precursor lesions.
  • These precursors include the intraductal papillary mucinous neoplasm, the mucinous cystic neoplasm, and pancreatic intraepithelial neoplasia.
  • Intraductal papillary mucinous neoplasms are grossly visible mucin-producing epithelial neoplasms that arise in the main pancreatic duct or one of its branches.
  • The cysts of mucinous cystic neoplasms do not communicate with the major pancreatic ducts, and these neoplasms are characterized by a distinct ovarian-type stroma.
  • Pancreatic intraepithelial neoplasia is a microscopic lesion.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2585-8 [12750283.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):147-55 [14505148.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1086-94 [14614047.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):735-42 [14966099.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Pancreas. 2004 Apr;28(3):282-8 [15084972.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):232-6 [8654602.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] Nat Genet. 1997 May;16(1):17-8 [9140390.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21 [9641496.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]
  • [Cites] Ann Diagn Pathol. 1998 Oct;2(5):286-92 [9845751.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2001-8 [9951854.001]
  • [Cites] Eur J Surg. 1999 Jan;165(1):43-8 [10069633.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):281-5 [10526064.001]
  • [Cites] Arch Surg. 1960 Nov;81:683-9 [13738110.001]
  • [Cites] J Clin Pathol. 1962 Sep;15:432-7 [14018131.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):141-7 [15782177.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):959-63 [15832197.001]
  • [Cites] PLoS Med. 2004 Dec;1(3):e65 [15630470.001]
  • [Cites] World J Gastroenterol. 2005 Sep 28;11(36):5688-90 [16237766.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):36-41 [16330940.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Radiology. 2006 Mar;238(3):912-9 [16439566.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Surgery. 2006 Jun;139(6):749-54 [16782429.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1265-70 [16979953.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2236-45 [17103100.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e516 [17194196.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1417-22 [17416862.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Cancer. 1979 Apr;43(4):1418-28 [445339.001]
  • [Cites] Tohoku J Exp Med. 1982 Jun;137(2):115-24 [7112540.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982 Aug;396(3):331-49 [7135827.001]
  • [Cites] Am Surg. 1984 Apr;50(4):225-9 [6712017.001]
  • [Cites] Am J Surg Pathol. 1987 Jan;11(1):11-20 [3789255.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Pathobiology. 1991;59(1):46-52 [1675057.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):651-6 [1309676.001]
  • [Cites] Eur J Surg. 1995 Jan;161(1):35-40 [7727604.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):970-4 [7666916.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):205-12 [10674612.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Eur J Surg. 2000 Feb;166(2):141-8 [10724492.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6 [10922411.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Int J Cancer. 2000 Sep 15;87(6):809-11 [10956390.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1544-8 [11075857.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jan;176(1):179-85 [11133563.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):139-46 [11266517.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):638-42 [11431719.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer J. 2001 Jul-Aug;7(4):251-8 [11561601.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3789-93 [12097290.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Pancreatology. 2001;1(6):648-55 [12120249.001]
  • [Cites] J Clin Gastroenterol. 2002 Aug;35(2):175-9 [12172364.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Langenbecks Arch Surg. 2002 Nov;387(7-8):281-5 [12447553.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):437-43 [12447672.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):525-30 [12478670.001]
  • (PMID = 17996793.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062924-130011; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-130011
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  • [Other-IDs] NLM/ NIHMS35907; NLM/ PMC2194627
  •  go-up   go-down


88. Gbelcová H, Lenícek M, Zelenka J, Knejzlík Z, Dvoráková G, Zadinová M, Poucková P, Kudla M, Balaz P, Ruml T, Vítek L: Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer; 2008 Mar 15;122(6):1214-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in antitumor effects of various statins on human pancreatic cancer.
  • The aim of the present study was to compare the effects of the individual commercially available statins on experimental pancreatic cancer.
  • The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human pancreatic cancer were evaluated in CAPAN-2, BxPc-3 and MiaPaCa-2 cell lines.
  • In summary, substantial tumor-suppressive effects of various statins on the progression of experimental pancreatic adenocarcinoma were demonstrated, with marked differences among individual statins.
  • These results support greatly the potential of statins for the chemoadjuvant treatment of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18027870.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


89. Funamizu N, Aramaki M, Matsumoto T, Inomata M, Shibata K, Himeno Y, Yada K, Hirano S, Sasaki A, Kawano K, Kitano S: Groove pancreatic carcinoma. Hepatogastroenterology; 2009 Nov-Dec;56(96):1742-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Groove pancreatic carcinoma.
  • The groove area is localized between the head of the pancreas, the duodenum, and the common bile duct.
  • Differentiating of groove pancreatitis from pancreatic carcinoma is often difficult.
  • Herein, we report a 54-year-old woman with groove pancreatic adenocarcinoma presenting epigastralgia, jaundice, and vomiting.
  • The diagnosis was confirmed by computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), and endoscopic biopsy.
  • Microscopically, well-differentiated adenocarcinoma was mainly located in Santorini's duct, but there was no invasion to the main pancreatic duct.
  • It is very difficult to differentiate groove pancreatic carcinoma from groove pancreatitis.
  • To avoid unnecessary surgical treatment, endoscopic biopsy and observation of the duodenum are useful for diagnosis.
  • However, keeping in mind the differential diagnosis of pancreatic head carcinoma is necessary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Pancreatitis, Chronic / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214229.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


90. Ridolfini MP, Gourgiotis S, Alfieri S, Di Miceli D, Rotondi F, Limongelli F, Quero G, Larghi A, Cazzato MT, Martella N, Doglietto GB: [Presentation, treatment and prognosis of intraductal papillary mucinous neoplasm]. Ann Ital Chir; 2007 Jul-Aug;78(4):257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms (IPMNs) are rare tumours rising from the pancreatic duct epithelium.
  • They are characterized by intraductal papillary growth and thick mucin secretion; mucin fills the Wirsung and/or branch pancreatic ducts and may cause ductal dilatation.
  • Recent advances in diagnostic imaging have led to an increased frequency of diagnosis of IPMNs, but the clinical features of them can range broadly from benign, borderline, and malignant non-invasive to invasive lesions, and their management has not yet been clearly defined.
  • Endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasonography (EUS), intraductal ultrasonography, and magnetic resonance cholangiopancreatography (MRCP) are the most valuable imaging techniques for diagnosis of these lesions.
  • Total pancreatectomy should be reserved for patients with resectable but extensive IPMN involving the whole pancreas; its benefits must be balanced against perioperative risks.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms
  • [MeSH-minor] Aged. Diagnosis, Differential. Dilatation, Pathologic / etiology. Female. Humans. Male. Middle Aged. Pancreatic Ducts. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990599.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 75
  •  go-up   go-down


91. Chatzipantelis P, Karvouni E, Fragoulidis GP, Voros D, Pafiti A: Clinicopathologic features of two rare cases of mesenchymal metastatic tumors in the pancreas: review of the literature. Pancreas; 2006 Oct;33(3):301-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of two rare cases of mesenchymal metastatic tumors in the pancreas: review of the literature.
  • OBJECTIVES: A clinicopathologic presentation of 2 unusual cases of metastatic mesenchymal neoplasms in the pancreas.
  • Distal pancreatectomy and splenectomy was performed because of suspicious mass in the pancreas.
  • She underwent distal pancreatectomy and splenectomy because of suspicious mass measuring 4 x 4 cm, in the pancreatic body.
  • RESULTS: In the first case, the pathological examination revealed a tumor measuring 3.8 x 3.5 cm and histologically compatible with me